UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM

10-Q

(Mark One)

☒	~~QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~November 30, 2022.~~

February 28, 2023.

or

☐	~~TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

to

Commission file number

0-17988

Neogen Corporation

(Exact name of registrant as specified in its charter)


Michigan		38-2367843
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification Number)

620 Lesher Place

Lansing, Michigan48912

(Address of principal executive offices, including zip code)

~~(517)~~

(517) 372-9200

(Registrant’s telephone number, including area code)

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:

Title of each Class

Trading
Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.16 par value per share

NEOG

~~NEOG~~

NASDAQ Global Select Market

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. YES☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation

S-T

(§ (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

YES

☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a

non-accelerated

filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule

12b-2

of the Exchange Act.


Large accelerated filer	☒	☒	Accelerated filer	☐
Non-accelerated filer	☐	☐	Smaller Reporting Company	☐
Emerging growth company	☐	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule

12b-2

of the Exchange Act): YES ☐ NO

☒

As of ~~November 30, 2022~~February 28, 2023 there were ~~216,154,283~~216,220,821 shares of Common Stock outstanding.

NEOGEN CORPORATION AND SUBSIDIARIES

TABLE OF CONTENTS


			Page No.
PART I. FINANCIAL INFORMATION


Item 1.		Interim Condensed Consolidated Financial Statements (unaudited)		2
		Condensed Consolidated Balance Sheets – ~~November 30, 2022~~February 28, 2023 and May 31, 2022		2
		Condensed Consolidated Statements of Income (Loss) – Three and ~~six~~nine months ended ~~November 30,~~February 28, 2023 and 2022 ~~and 2021~~		3
		Condensed Consolidated Statements of Comprehensive Income (Loss) – Three and ~~six~~nine months ended ~~November 30,~~February 28, 2023 and 2022 ~~and 2021~~		4
		Condensed Consolidated Statements of Equity – Three and ~~six~~nine months ended ~~November 30,~~February 28, 2023 and 2022 ~~and 2021~~		5
		Condensed Consolidated Statements of Cash Flows – ~~Six~~Nine months ended ~~November 30,~~February 28, 2023 and 2022 ~~and 2021~~		6
		Notes to Interim Condensed Consolidated Financial Statements – ~~November 30, 2022~~February 28, 2023		7
Item 2.		Management’s Discussion and Analysis of Financial Condition and Results of Operations		24	27
Item 3.		Quantitative and Qualitative Disclosures About Market Risk		36	39
Item 4.		Controls and Procedures		36	40

PART II. OTHER INFORMATION

~~Item 1.~~		~~Legal Proceedings~~		37

~~Item 1A.~~		~~Risk Factors~~		37
~~Item 6.~~		~~Exhibits~~		38

~~SIGNATURES~~			39
Item 1.	Legal Proceedings		40
Item 1A.	Risk Factors		40
Item 6.	Exhibits		41

SIGNATURES			42

	CEO Certification

		CFO Certification

		Section 906 Certification

1

PART I – FINANCIAL INFORMATION

Item 1. Interim Condensed Consolidated Financial Statements

Neogen Corporation and Subsidiaries

Condensed Consolidated Balance Sheets (unaudited)

(in thousands, except share and

per share amounts)

November 30,
2022

May 31,

2022

Assets

Current Assets

Cash and cash equivalents
   $ 100,000 $ 44,473
Marketable securities
   176,338 336,578
Accounts receivable, net of allowance of $1,950 and $1,650
   142,711 99,674
Inventories
   136,069 122,313
Prepaid expenses and other current assets
   88,215 23,760


Total Current Assets
   643,333 626,798
Net Property and Equipment
   148,170 110,584
Other Assets

Right of use assets
   3,707 3,184
Goodwill
   2,122,397 142,704
Other
non-amortizable
intangible assets
   15,216 15,397
Amortizable intangible and other assets, net of accumulated amortization of $78,046 and $55,416
   1,626,514 92,106
Other
non-current
assets
   3,905 2,156


Total Assets
   $ 4,563,242 $ 992,929


Liabilities and Stockholders’ Equity

Current Liabilities

Accounts payable
   $ 79,251 $ 34,614
Accrued compensation
   15,014 11,123
Income tax payable
   9,049 2,126
Accrued interest
   13,974 —
Deferred revenue
   5,083 5,460
Other accruals
   30,187 24,521


Total Current Liabilities
   152,558 77,844
Deferred Income Tax Liability
   364,252 17,011
Non-current
debt
   923,962 —
Other
non-current
liabilities
   16,207 10,700


Total Liabilities
   1,456,979 105,555
Commitments and Contingencies
(note 12)

Equity

Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding
   —    —
Common stock, $0.16 par value, 315,000,000 shares authorized, 216,154,283 and 107,801,094 shares issued and outstanding at November 30, 2022 and May 31, 2022, respectively
   34,584 17,248
Additional
paid-in
capital
   2,560,898 309,984
Accumulated other comprehensive loss
   (40,498 ) (27,769 )
Retained earnings
   551,279 587,911


Total Stockholders’ Equity
   3,106,263 887,374


Total Liabilities and Stockholders’ Equity
   $     4,563,242 $     992,929

~~See~~


	February 28, 2023			May 31, 2022
Assets
Current Assets
Cash and cash equivalents	$	67,134		$	44,473
Marketable securities		116,080			336,578
Accounts receivable, net of allowance of $2,200 and $1,650		146,393			99,674
Inventories		143,863			122,313
Prepaid expenses and other current assets		81,901			23,760
Total Current Assets		555,371			626,798
Net Property and Equipment		164,888			110,584
Other Assets
Right of use assets		5,062			3,184
Goodwill		2,135,118			142,704
Other non-amortizable intangible assets		14,252			15,397
Amortizable intangible and other assets, net of accumulated amortization		1,620,229			92,106
Other non-current assets		13,844			2,156
Total Assets	$	4,508,764		$	992,929
Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable	$	60,494		$	34,614
Accrued compensation		17,387			11,123
Income tax payable		1,645			2,126
Accrued interest		3,438			—
Deferred revenue		6,765			5,460
Other accruals		17,426			24,521
Total Current Liabilities		107,155			77,844
Deferred Income Tax Liability		362,630			17,011
Non-current debt		884,701			—
Other non-current liabilities		28,723			10,700
Total Liabilities		1,383,209			105,555
Commitments and Contingencies (note 12)
Equity
Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding		—			—
Common stock, $0.16 par value, 315,000,000 shares authorized, 216,220,821 and 107,801,094 shares issued and outstanding at February 28, 2023 and May 31, 2022, respectively		34,595			17,248
Additional paid-in capital		2,564,713			309,984
Accumulated other comprehensive loss		(33,222	)		(27,769	)
Retained earnings		559,469			587,911
Total Stockholders’ Equity		3,125,555			887,374
Total Liabilities and Stockholders’ Equity	$	4,508,764		$	992,929

The accompanying notes ~~to interim~~are an integral part of these condensed consolidated financial statements.

2

Neogen Corporation and Subsidiaries

Condensed Consolidated Statements of Income (Loss) (unaudited)

(in thousands, except per share amounts)

Three Months Ended
November 30,

Six Months Ended
November 30,


2022

2021

2022

2021

Revenues

Product revenues
   $ 203,317 $ 106,111
$ 310,109 $ 210,124
Service revenues
   26,716 24,406
52,273 48,698


Total Revenues
   230,033 130,517
362,382 258,822
Cost of Revenues


Cost of product revenues
   102,530 56,374
157,971 111,100
Cost of service revenues
   14,964 13,549
29,602 27,120


Total Cost of Revenues
   117,494 69,923
187,573 138,220


Gross Margin
   112,539 60,594
174,809 120,602
Operating Expenses


Sales and marketing
   36,348 21,188
59,731 41,743
General and administrative
   77,001 22,605
104,945 35,988
Research and development
   6,846 4,332
11,727 8,657


Total Operating Expenses
   120,195 48,125
176,403 86,388


Operating Income (Loss)
   (7,656 ) 12,469
(1,594 ) 34,214
Other Income (Expense)


Interest income
   553 246
1,523 455
Interest expense    (20,545 ) (22 ) (20,547 ) (28 )
Other income (expense)
   (6,443 ) 235
(6,814 ) 14


Total Other Income (Expense)
   (26,435 ) 459
(25,838 ) 441


Income (Loss) Before Taxes
   (34,091 ) 12,928
(27,432 ) 34,655
Provision for Income Taxes
   7,750 2,100
9,200 6,750


Net Income (Loss)
   $ (41,841 ) $ 10,828
$ (36,632 ) $ 27,905


Net Income (Loss) Per Share


Basic
   $ (0.19 ) $ 0.10
$ (0.23 ) $ 0.26
Diluted
   $ (0.19 ) $ 0.10
$ (0.23 ) $ 0.26
Weighted Average Shares Outstanding


Basic
   216,134 107,641
161,690 107,565
Diluted
   216,134 108,122
161,690 108,099

~~See~~


	Three Months Ended February 28,						Nine Months Ended February 28,
	2023			2022			2023			2022
Revenues
Product revenues	$	190,688		$	101,566		$	500,797		$	311,701
Service revenues		27,567			26,678			79,840			75,365
Total Revenues		218,255			128,244			580,637			387,066
Cost of Revenues
Cost of product revenues		94,377			56,550			252,348			167,650
Cost of service revenues		15,914			14,282			45,516			41,402
Total Cost of Revenues		110,291			70,832			297,864			209,052
Gross Margin		107,964			57,412			282,773			178,014
Operating Expenses
Sales and marketing		38,598			21,477			98,329			63,220
General and administrative		46,424			24,997			151,369			60,985
Research and development		7,258			4,561			18,985			13,218
Total Operating Expenses		92,280			51,035			268,683			137,423
Operating Income		15,684			6,377			14,090			40,591
Other (Expense) Income
Interest income		640			349			2,163			804
Interest expense		(17,460	)		(35	)		(38,007	)		(63	)
Other expense		(1,124	)		(48	)		(7,938	)		(34	)
Total Other (Expense) Income		(17,944	)		266			(43,782	)		707
(Loss) Income Before Taxes		(2,260	)		6,643			(29,692	)		41,298
Provision for Income Taxes		(10,450	)		1,200			(1,250	)		7,950
Net Income (Loss)	$	8,190		$	5,443		$	(28,442	)	$	33,348
Net Income (Loss) Per Share
Basic	$	0.04		$	0.05		$	(0.16	)	$	0.31
Diluted	$	0.04		$	0.05		$	(0.16	)	$	0.31
Weighted Average Shares Outstanding
Basic		216,218			107,818			179,666			107,648
Diluted		216,399			108,133			179,666			108,130

The accompanying notes ~~to interim~~are an integral part of these condensed consolidated financial statements.

3

Neogen Corporation and Subsidiaries

Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited)

(in thousands)

Three Months Ended
November 30,

Six Months Ended
November 30,


2022

2021

2022

2021

Net income (loss)
   $ (41,841 ) $     10,828 $ (36,632 ) $ 27,905
Foreign currency translations
   1,102 (7,649 ) (10,031 ) (12,272 )
Unrealized gain (loss) on marketable securities, net of tax
   154 (382 ) (270 ) (588 )
Unrealized loss on derivative instruments, net of tax
   (2,428 ) —   (2,428 ) —


Total comprehensive income (loss)
   $ (43,013 ) $ 2,797 $ (49,361 ) $ 15,045

~~See~~


	Three Months Ended February 28,					Nine Months Ended February 28,
	2023		2022			2023			2022
Net income (loss)	$	8,190	$	5,443		$	(28,442	)	$	33,348
Foreign currency translations		3,354		2,789			(6,677	)		(9,482	)
Unrealized gain (loss) on marketable securities, net of tax		944		(993	)		674			(1,582	)
Unrealized gain on derivative instruments, net of tax		2,978		—			550			—
Total comprehensive income (loss)	$	15,466	$	7,239		$	(33,895	)	$	22,284

The accompanying notes ~~to interim~~are an integral part of these condensed consolidated financial statements.

4

Neogen Corporation and Subsidiaries

Condensed Consolidated Statements of

Equity (unaudited)

(in thousands)

Additional

Accumulated
Other


Common Stock

Paid-in

Comprehensive

Retained


Shares

Amount

Capital

Loss

Earnings

Total

Balance, June 1, 2022


107,801


$
17,248


$
309,984


$
(27,769
)

$
587,911

$
887,374

Exercise of options and share-based compensation expense
   4    1    1,904    —   —   1,905
Issuance of shares under employee stock purchase plan
   33    5    862    —   —   867
Net income for the three months ended August 31, 2022
   —      —      —      —   5,209 5,209
Other comprehensive loss for the three months ended August 31, 2022
   —      —      —      (11,557 ) —   (11,557 )








Balance, August 31, 2022


107,838


$
17,254


$
312,750


$
(39,326
)

$
593,120

$
883,798

Exercise of options and share-based compensation expense
   46    7    2,630    —   —   2,637
Issuance of shares for 3M transaction
   108,270    17,323    2,245,518    2,262,841
Net loss for the three months ended November 30, 2022
   —      —      —      —   (41,841 ) (41,841 )
Other comprehensive loss for the three months ended November 30, 2022
   —      —      —      (1,172 ) —   (1,172 )








Balance, November 30, 2022


216,154


$
34,584


$
2,560,898


$
(40,498
)

$
551,279

$
3,106,263

Accumulated


Additional

Other


Common Stock

Paid-in

Comprehensive

Retained


Shares

Amount

Capital

Loss

Earnings

Total

Balance, June 1, 2021


107,468


$
17,195


$
294,953


$
(11,375
)

$
539,604


$
840,377

Exercise of options and share-based compensation expense
   6    1    1,838    —   —      1,839
Issuance of shares under employee stock purchase plan
   19    3    896    —   —      899
Net income for the three months ended August 31, 2021
   —      —      —      —   17,077    17,077
Other comprehensive loss for the three months ended August 31, 2021
   —      —      —      (4,829 ) —      (4,829 )










Balance, August 31, 2021


107,493


$
17,199


$
297,687


$
(16,204
)

$
556,681


$
855,363

Exercise of options and share-based compensation expense
   275    44    7,272    —   —      7,316
Net income for the three months ended November 30, 2021
   —      —      —      —   10,828    10,828
Other comprehensive loss for the three months ended November 30, 2021
   —      —      —      (8,031 ) —      (8,031 )










Balance, November 30, 2021


107,768


$
17,243


$
304,959


$
(24,235
)

$
567,509


$
865,476

~~See~~


					Additional		Accumulated Other
	Common Stock				Paid-in		Comprehensive			Retained
	Shares		Amount		Capital		Loss			Earnings			Total
Balance, June 1, 2022		107,801	$	17,248	$	309,984	$	(27,769	)	$	587,911		$	887,374
Exercise of options and share-based compensation expense		4		1		1,904		—			—			1,905
Issuance of shares under employee stock purchase plan		33		5		862		—			—			867
Net income		—		—		—		—			5,209			5,209
Other comprehensive loss		—		—		—		(11,557	)		—			(11,557	)
Balance, August 31, 2022		107,838	$	17,254	$	312,750	$	(39,326	)	$	593,120		$	883,798
Exercise of options and share-based compensation expense		46		7		2,630		—			—			2,637
Issuance of shares for 3M transaction		108,270		17,323		2,245,518								2,262,841
Net loss		—		—		—		—			(41,841	)		(41,841	)
Other comprehensive loss		—		—		—		(1,172	)		—			(1,172	)
Balance, November 30, 2022		216,154	$	34,584	$	2,560,898	$	(40,498	)	$	551,279		$	3,106,263
Exercise of options and share-based compensation expense		5		1		2,834		—			—			2,835
Issuance of shares under employee stock purchase plan		62		10		981		—			—			991
Net income		—		—		—		—			8,190			8,190
Other comprehensive income		—		—		—		7,276			—			7,276
Balance, February 28, 2023		216,221	$	34,595	$	2,564,713	$	(33,222	)	$	559,469		$	3,125,555


							Accumulated
					Additional		Other
	Common Stock				Paid-in		Comprehensive			Retained
	Shares		Amount		Capital		Loss			Earnings		Total
Balance, June 1, 2021		107,468	$	17,195	$	294,953	$	(11,375	)	$	539,604	$	840,377
Exercise of options and share-based compensation expense		6		1		1,838		—			—		1,839
Issuance of shares under employee stock purchase plan		19		3		896		—			—		899
Net income		—		—		—		—			17,077		17,077
Other comprehensive loss		—		—		—		(4,829	)		—		(4,829	)
Balance, August 31, 2021		107,493	$	17,199	$	297,687	$	(16,204	)	$	556,681	$	855,363
Exercise of options and share-based compensation expense		275		44		7,272		—			—		7,316
Net income		—		—		—		—			10,828		10,828
Other comprehensive loss		—		—		—		(8,031	)		—		(8,031	)
Balance, November 30, 2021		107,768	$	17,243	$	304,959	$	(24,235	)	$	567,509	$	865,476
Exercise of options and share-based compensation expense		26		4		1,848		—			—		1,852
Issuance of shares under employee stock purchase plan		24		4		973		—			—		977
Net income		—		—		—		—			5,443		5,443
Other comprehensive income		—		—		—		1,796			—		1,796
Balance, February 28, 2022		107,818	$	17,251	$	307,780	$	(22,439	)	$	572,952	$	875,544

The accompanying notes ~~to interim~~are an integral part of these condensed consolidated financial statements.

5

Neogen Corporation and Subsidiaries

Condensed Consolidated Statements of Cash Flows (unaudited)

(in thousands)

Six Months Ended
November 30,


2022

2021

Cash Flows (For) From Operating Activities

Net Income (Loss)
   $ (36,632 ) $ 27,905
Adjustments to reconcile net income to net cash (for) from operating activities:

Depreciation and amortization
   32,467 11,511
Deferred income taxes
   (1,983 ) (88 )
Share-based compensation
   4,499 3,438
Disposal of property and equipment    (456 ) —
Change in operating assets and liabilities, net of business acquisitions:

Accounts receivable
   (44,452 ) (1,500 )
Inventories
   6,478 (6,929 )
Prepaid expenses and other current assets
   (37,833 ) (3,709 )
Accounts payable, accruals and other changes
   30,070 10,429
Financing fee amortization    999 —
Interest expense accrual    13,974 —


Net Cash (For) From Operating Activities

   (32,869 ) 41,057
Cash Flows (For) From Investing Activities

Purchases of property, equipment and other
non-current
intangible assets
   (25,102 ) (5,235 )
Proceeds from the sale of marketable securities
   172,763 197,941
Purchases of marketable securities
   (12,523 ) (230,586 )
Proceeds from the sale of property and equipment    606 —
Business acquisitions, net of working capital adjustments and cash acquired
   38,896 (26,864 )


Net Cash (For) From Investing Activities
   174,640 (64,744 )
Cash Flows (For) From Financing Activities

Exercise of stock options and issuance of employee stock purchase plan shares
   920 6,619
Financing fees paid    (19,276 ) —
Repayment of debt    (60,000 ) —


Net Cash (For) From Financing Activities
   (78,356 ) 6,619
Effect of Foreign Exchange Rates on Cash
   (7,888 ) (7,415 )


Net Increase (Decrease) In Cash and Cash Equivalents
   55,527 (24,483 )
Cash and Cash Equivalents, Beginning of Period
   44,473 75,602


Cash and Cash Equivalents, End of Period
   $ 100,000 $ 51,119

~~See~~


	Nine Months Ended February 28,
	2023			2022
Cash Flows (For) From Operating Activities
Net (Loss) Income	$	(28,442	)	$	33,348
Adjustments to reconcile net (loss) income to net cash (for) from operating activities:
Depreciation and amortization		59,938			17,833
Impairment of discontinued product lines		2,300			—
Loss on sale of minority interest		1,516			—
Deferred income taxes		(5,299	)		(720	)
Share-based compensation		7,311			5,045
Disposal of property and equipment		(472	)		—
Financing fee amortization		1,860			—
Change in operating assets and liabilities, net of business acquisitions:
Accounts receivable		(47,535	)		(883	)
Inventories		(656	)		(11,956	)
Prepaid expenses and other current assets		(31,896	)		(3,824	)
Accounts payable, accruals and other changes		(8,422	)		(5,652	)
Change in other non-current assets and non-current liabilities		(3,579	)		14,457
Interest expense accrual		3,438			—
Net Cash (For) From Operating Activities		(49,938	)		47,648
Cash Flows From (For) Investing Activities
Purchases of property, equipment and other non-current intangible assets		(40,253	)		(11,891	)
Proceeds from the sale of marketable securities		233,020			284,367
Purchases of marketable securities		(12,523	)		(314,442	)
Proceeds from the sale of property and equipment		682			—
Business acquisitions, net of working capital adjustments and cash acquired		13,237			(38,164	)
Net Cash From (For) Investing Activities		194,163			(80,130	)
Cash Flows (For) From Financing Activities
Exercise of stock options and issuance of employee stock purchase plan shares		943			7,842
Financing fees paid		(19,276	)		—
Repayment of debt		(100,000	)		—
Net Cash (For) From Financing Activities		(118,333	)		7,842
Effect of Foreign Exchange Rates on Cash		(3,231	)		(8,083	)
Net Increase (Decrease) In Cash and Cash Equivalents		22,661			(32,723	)
Cash and Cash Equivalents, Beginning of Period		44,473			75,602
Cash and Cash Equivalents, End of Period	$	67,134		$	42,879

The accompanying notes ~~to interim~~are an integral part of these condensed consolidated financial statements.

6

~~Table of Contents~~

NEOGEN CORPORATION AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

DESCRIPTION OF BUSINESS

Neogen Corporation and subsidiaries ("Neogen," "we," "our," or the "Company") develop, manufacture and market a diverse line of products and services dedicated to food and animal safety. Our Food Safety segment consists primarily of diagnostic test kits and complementary products (e.g., culture media) sold to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant

by-products,

meat speciation, drug residues, pesticide residues and general sanitation concerns. Our diagnostic test kits are generally easier to use and provide ~~greater accuracy and speed~~quicker results than conventional diagnostic methods. The majority of the test kits are disposable,

single-use,

immunoassay and DNA detection products that rely on proprietary antibodies and RNA and DNA testing methodologies to produce rapid and accurate test results. Our expanding line of food safety products also includes genomics-based diagnostic technology, and advanced software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.

Neogen’s Animal Safety segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides and genomics testing services for the worldwide animal safety market. The majority of these consumable products are marketed through veterinarians, retailers, livestock producers and animal health product distributors. Our line of drug detection products is sold worldwide for the detection of abused and therapeutic drugs in animals and animal products, and has expanded into the workplace and human forensic markets.

MERGER WITH THE FOOD SAFETY BUSINESS OF 3M

On September 1, 2022, the Company completed its merger (the “Merger”) with Garden SpinCo, a newly formed,

,

wholly owned subsidiary of 3M created to carve out 3M’s Food Safety Division (“3M FSD”, “FSD”), in a Reverse Morris Trust transaction. The purchase price consideration was

~~$3.2~~ $3.2 billion, net of customary purchase price adjustments and transaction costs, which consisted of 108.3 million shares of Neogen common stock issued on closing. Immediately following the transaction, Garden SpinCo stockholders owned, in the aggregate,

approximately ~~50.1%~~50.1% of the issued and outstanding shares of Neogen common stock and

pre-merger

Neogen shareholders owned, in the aggregate, approximately ~~49.9%~~49.9% of the issued and outstanding shares of Neogen common stock.

Neogen was deemed to be the accounting acquiror of the 3M FSD for accounting purposes under U.S. generally accepted accounting principles.

BASIS OF PRESENTATION AND CONSOLIDATION

The accompanying unaudited condensed consolidated financial statements include the accounts of Neogen Corporation (“Neogen” or the “Company”) and its wholly owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles) for interim financial information and with the instructions to Form

10-Q

and Article 10 of Regulation

S-X.

Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of the interim period have been included in the accompanying unaudited condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. The results of operations ~~for~~during the three and ~~six month periods~~nine months ended ~~November 30, 2022~~February 28, 2023 are not necessarily indicative of the results to be expected for the full fiscal year ending May 31, 2023. For more complete financial information, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on

Form 10-K

for the fiscal year ended May 31, 2022.

7

Our functional currency is the U.S. dollar. We translate our

non-U.S.

operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded in other comprehensive income (loss). Gains or losses from foreign currency transactions are included in other income (expense) on our condensed consolidated statements of

income (loss).

7

ACCOUNTING POLICIES

Comprehensive Income (Loss)

Comprehensive income (loss) represents net income and any revenues, expenses, gains and losses that, under U.S. generally accepted accounting principles, are excluded from net income and recognized directly as a component of equity. Accumulated other comprehensive income (loss) consists of foreign currency translation adjustments and unrealized gains or losses on our marketable securities and derivative instruments.

Fair Value of Financial Instruments

Fair value measurements are determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs. The Company utilizes a fair value hierarchy based upon the observability of inputs used in valuation techniques as follows:

Level 1: Observable inputs such as quoted prices in active markets;

Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The carrying amounts of certain financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, our revolving credit agreement, and long-term debt, approximate their fair value based on either their short maturity or current terms for similar instruments.

Leases

We lease various manufacturing, laboratory, warehousing and distribution facilities, administrative and sales offices, equipment and vehicles under operating leases. We evaluate our contracts to determine if an arrangement is a lease at inception and classify it as a finance or operating lease. Currently, all our leases are classified as operating leases. The Company recognizes a lease liability in the statement of financial position to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term.

Right-of-use

assets are recorded in ~~other assets~~Other Assets on our condensed consolidated balance sheets. Current and

non-current

lease liabilities are recorded in other accruals within current liabilities and other

non-current

liabilities, respectively, on our condensed consolidated balance sheets. Costs associated with operating leases are recognized on a straight-line basis within operating expenses over the term of the lease. The

right-of-use

assets were $

~~3,707,000~~5,062,000 and ~~$3,184,000 at November 30, 2022~~$3,184,000 as of February 28, 2023 and May 31, 2022, respectively. The total current and

non-current

lease liabilities were ~~$3,630,000~~$5,112,080 and ~~$3,228,000 at November 30, 2022~~$3,228,000 as of February 28, 2023 and May 31, 2022, respectively.

8

Derivatives

We operate on a global basis and are exposed to the risk that our financial condition, results of operations and cash flows could be adversely affected by changes in foreign currency exchange ~~rates.~~rates and changes in interest rates. To reduce the potential effects of foreign currency exchange rate movements on net earnings, we enter into derivative financial instruments in the form of foreign currency exchange forward contracts with major financial institutions and have also entered into interest rate swap contracts as a hedge against changes in interest rates. All derivatives are recognized as assets or liabilities and measured at fair value. For derivatives that are determined to be effective hedges, changes in fair value are recognized onin other comprehensive income (loss) until the underlying hedged item is recognized in earnings. Derivatives that are not determined to be effective hedges are adjusted to fair value with a corresponding adjustment to earnings. We do not use financial instruments for trading or speculative purposes.

ESTIMATES AND ASSUMPTIONS

The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including, but not limited to, variable consideration related to revenue recognition, allowances for doubtful accounts, the market value of, and demand for, inventories, stock-based compensation, provision for income taxes and related balance sheet accounts, accruals, goodwill and other intangible assets and derivatives. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

8

Accounts Receivable and Concentrations of Credit Risk

Financial instruments which potentially subject Neogen to concentrations of credit risk consist principally of accounts receivable. Management attempts to minimize credit risk by reviewing customers’ credit histories before extending credit and by monitoring credit exposure on a regular basis. Collateral or other security is generally not required for accounts receivable. We maintain an allowance for customer accounts that reduces receivables to amounts that are expected to be collected. In estimating the allowance for doubtful accounts, management considers relevant information about past events, current conditions and reasonable and supportable forecasts that affect the collectability of financial assets. Once a receivable balance has been determined to be uncollectible, generally after all collection efforts have been exhausted, that amount is charged against the allowance for doubtful accounts. No customer accounted for more than ~~10%~~10% of accounts receivable ~~November 30, 2022~~atFebruary 28, 2023 or May 31, 2022, respectively.

Inventory

The reserve for obsolete and slow-moving inventory is reviewed at least quarterly based on an analysis of the inventory, considering the current condition of the asset as well as other known facts and future plans. The reserve required to record inventory at lower of cost or net realizable value is adjusted as conditions change. Product obsolescence may be caused by shelf-life expiration, discontinuance of a product line, replacement products in the marketplace or other competitive situations.

Goodwill and Other Intangible Assets

Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses after amounts are allocated to other identifiable intangible assets. Other intangible assets include customer relationships, trademarks, licenses, trade names, covenants

not-to-compete

and patents. Customer-based intangibles are amortized on either an accelerated or straight-line basis, reflecting the pattern in which the economic benefits are consumed, while all other amortizable intangibles are amortized on a straight-line ~~basis; intangibles~~basis. Intangibles are generally amortized over 5 to 25 ~~years.~~years. We review the carrying amounts of goodwill and other

non-amortizable

intangible assets annually, or when indications of impairment exist, to determine if such assets may be impaired. If the carrying amounts of these assets are deemed to be less than fair value based upon a discounted cash flow analysis and comparison to comparable EBITDA multiples of peer companies, such assets are reduced to their estimated fair value and a charge is recorded to operations.

9

Long-Lived Assets

Management reviews the carrying values of its long-lived assets to be held and used, including definite-lived intangible assets, for

possible impairment whenever events or changes in business conditions warrant such a review. The carrying value of a long-lived asset is considered impaired when the anticipated separately identifiable undiscounted cash flows over the remaining useful life of the asset indicate that the carrying amount of the asset may not be recoverable. In such an event, fair value is determined using discounted cash flows and, if lower than the carrying value, impairment is recognized through a charge to operations.

Business Combinations

We utilize the acquisition method of accounting for business combinations. This method requires, among other things, that results of operations of acquired companies are included in Neogen’s results of operations beginning on the respective acquisition dates and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Any excess of the fair value of consideration transferred over the fair values of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized at the estimated fair value on the acquisition ~~date; these~~date. These amounts are recorded in either other accruals within current liabilities (for expected payments ~~in less than a year)~~to be made within the next 12 months) or other

non-current

liabilities (for expected payments ~~in greater than a year)~~to be made after the next 12 months), both on our condensed consolidated balance sheets. Subsequent changes to the fair value of contingent consideration liabilities are recognized in other income (expense) in the condensed consolidated statements of income

(loss)

. Contingent consideration payments made soon after the acquisition date are classified as investing activities in the condensed consolidated statements of cash flows. Contingent consideration payments not made soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the condensed consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are reported as operating activities in the condensed consolidated statements of cash flows. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other business acquisition costs are expensed when incurred.

9

Equity Compensation Plans

Share options awarded to employees, restricted stock units (RSUs) and shares of stock awarded to employees under certain stock purchase plans are recognized as compensation expense based on their fair value at grant date. The fair market value of options granted under the Company stock option plans was estimated on the date of grant using the Black-Scholes option-pricing model with assumptions for inputs such as interest rates, expected dividends, an estimate of award forfeitures, volatility measures and specific employee exercise behavior patterns based on statistical data. Some of the inputs used are not market-observable and have to be estimated or derived from available data. Use of different estimates would produce different option values, which in turn would result in higher or lower compensation expense recognized. For RSUs, we use the intrinsic value method to value the units.

To value equity awards, several recognized valuation models exist; none of these models can be singled out as being the best or most correct. The model applied by us can accommodate most of the specific features included in the options granted, which are the reason for their use. If different models were used, the option values could differ despite using the same inputs. Accordingly, using different assumptions coupled with using a different valuation model could have a significant impact on the fair value of employee stock options. Fair value could be either higher or lower than the number provided by the model applied and the inputs used. Further information on our equity compensation plans, including inputs used to determine the fair value of options, is disclosed in Note 7.

10

Income Taxes

We account for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and for tax credit carryforwards and are measured using the enacted tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax expense represents the change in net deferred income tax assets and liabilities during the year.

~~New~~

Accounting Pronouncements ~~Not Yet~~Recently Adopted

Acquired contract assets and liabilities in a business combination

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which amends ASC 805 to require an acquirer to, at the date of acquisition, recognize and measure contract assets and contract liabilities acquired in accordance with ASU 2014-9, Revenue from Contracts with Customers (Topic 606) as if the entity had originated the contracts. The guidance is effective for fiscal years beginning after December 15, 2022. ~~The Company will adopt~~We adopted this ~~guidance~~standard in the ~~event~~third quarter of fiscal 2023 and applied the amendment retrospectively to all business combinations in fiscal year 2023. Adoption of this standard did not have a ~~business combination subsequent to the effective date of the guidance.~~

material impact on our condensed consolidated financial statements and related disclosures.

~~Accounting Pronouncements Recently Adopted~~

Reference Rate Reform

In March 2020, the FASB issued Update

2020-04,

Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This update provides temporary optional expedients to applying the reference rate reform guidance to contracts that reference LIBOR or another reference rate expected to be discontinued. Under this update, contract modifications resulting in a new reference rate may be accounted for as a continuation of the existing contract. We adopted this standard in the second quarter of fiscal 2023, and now use the Secured Overnight Financing Rate (SOFR). Adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures.

2. CASH AND MARKETABLE SECURITIES

Cash and Cash Equivalents

Cash and cash equivalents consist of bank demand accounts, savings deposits, certificates of deposit and commercial paper with original maturities of 90 days or less. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has not experienced losses related to these balances and believes it is not exposed to significant credit risk regarding its cash and cash equivalents. Cash and cash equivalents were ~~$100,000,000~~$67,134,000 and $

44,473,000

~~at November 30, 2022~~ as of February 28, 2023 and May 31, 2022, respectively. The carrying value of these assets approximates fair value due to the short maturity of these instruments and is classified as Level 1 in the fair value hierarchy.

Marketable Securities

The Company has marketable securities held by banks or broker-dealers ~~at November 30, 2022.~~as of February 28, 2023. Changes in market value are monitored and recorded on a monthly ~~basis; in~~basis. In the event of a downgrade in credit quality subsequent to purchase, the marketable securities investment is evaluated to determine the appropriate action to take to minimize the overall risk to our marketable securities portfolio. These securities are classified as available for sale. The primary objective of management’s short-term investment activity is to preserve capital for the purpose of funding current operations, capital expenditures and business acquisitions; short-term investments are not entered into for trading or speculative purposes. These securities

10

are recorded at fair value based on recent trades or pricing models and therefore meet the Level 2 criteria. Interest income on these investments is recorded within other income on the income statement. Adjustments in the fair value of these assets are recorded in other comprehensive income.

11

Marketable Securities as of ~~November 30, 2022~~February 28, 2023 and May 31, 2022 are listed below by classification and remaining maturities.


(in thousands)	Maturity	February 28, 2023		May 31, 2022
Commercial Paper & Corporate Bonds	0 - 90 days	$	34,443	$	106,497
	91 - 180 days		22,322		61,373
	181 days - 1 year		52,462		91,706
	1 - 2 years		6,853		77,002
Total Marketable Securities		$	116,080	$	336,578

(in thousands)

Maturity

November 30,
2022

May 31,
2022

Commercial Paper & Corporate Bonds
   0 - 90 days    $ 61,104    $ 106,497
   91 - 180 days    34,200    61,373
   181 days - 1 year    57,151    91,706
   1 - 2 years    23,883    77,002




Total Marketable Securities
      $ 176,338    $ 336,578

The components of marketable securities, consisting of commercial paper and corporate bonds, ~~at November 30, 2022~~as of February 28, 2023 are as follows:

(in thousands)

Amortized
Cost

Unrealized
Gains

Unrealized
Losses

Fair Value

Commercial Paper & Corporate Bonds
   $ 179,650    $ —      $ (3,312 )    $ 176,338


(in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial Paper & Corporate Bonds	$	118,166	$	—	$	(2,086	)	$	116,080

The components of marketable securities, consisting of commercial paper and corporate bonds, atas of May 31, 2022 are as follows:


(in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial Paper & Corporate Bonds	$	339,540	$	7	$	(2,969	)	$	336,578

(in thousands)

Amortized
Cost

Unrealized
Gains

Unrealized
Losses

Fair Value

Commercial Paper & Corporate Bonds
   $ 339,540    $ 7    $ (2,969 )    $ 336,578

3. INVENTORIES

Inventories are stated at the lower of cost, determined by the

first-in,

first-out

method, or net realizable value. The components of inventories follow:


(in thousands)	February 28, 2023		May 31, 2022
Raw materials	$	73,514	$	58,667
Work-in-process		7,054		6,388
Finished and purchased goods		63,295		57,258
	$	143,863	$	122,313

(in thousands)

November 30,
2022

May 31,
2022

Raw materials
   $ 68,884    $ 58,667
Work-in-process
   6,013    6,388
Finished and purchased goods
   61,172    57,258




   $ 136,069    $ 122,313

11

4. REVENUE RECOGNITION

The Company determines the amount of revenue to be recognized through application of the following steps:

•

Identification of the contract with a customer;

•

Identification of the performance obligations in the contract;

•

Determination of the transaction price;

•

Allocation of the transaction price to the performance obligations in the contract; and

•

Recognition of revenue when, or as, the Company satisfies the performance obligations.

Essentially all of Neogen’s revenue is generated through contracts with its customers. A performance obligation is a promise in a contract to transfer a product or service to a customer. We generally recognize revenue at a point in time when all of our performance obligations under the terms of a contract are satisfied. Revenue is recognized upon transfer of control of promised products and services in an amount that reflects the consideration we expect to receive in exchange for those products or services. The collectability of consideration on the contract is reasonably assured before revenue is recognized. To the extent that customer payment has been received before all recognition criteria are met, these revenues are initially deferred in other accruals on the balance sheet and the revenue is recognized in the period that all recognition criteria have been met.

12

Certain agreements with customers include discounts or rebates on the sale of products and services applied retrospectively, such as volume rebates achieved by purchasing a specified purchase threshold of goods and services. We account for these discounts as variable consideration and estimate the likelihood of a customer meeting the threshold in order to determine the transaction price using the most predictive approach. We typically use the most-likely-amount method for incentives that are offered to individual customers, and the expected-value method for programs that are offered to a broad group of customers. Variable consideration reduces the amount of revenue that is recognized. Rebate obligations related to customer incentive programs are recorded in accrued liabilities; the rebate estimates are adjusted at the end of each applicable measurement period based on information currently available.

The performance obligations in Neogen’s contracts are generally satisfied well within one year of contract inception. In such cases, management has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. Management has elected to utilize the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred because the amortization period for the prepaid costs that would otherwise have been deferred and amortized is one year or less. We account for shipping and handling for products as a fulfillment activity when goods are shipped. Shipping and handling costs that are charged to and reimbursed by the customer are recognized as revenues, while the related expenses incurred by Neogen are recorded in sales and marketing expense. Revenue is recognized net of any tax collected from ~~customers; the~~customers. The taxes are subsequently remitted to governmental authorities. Our terms and conditions of sale generally do not provide for returns of product or reperformance of service except in the case of quality or warranty issues. These situations are ~~infrequent;~~infrequent, and due to immateriality of the amount, warranty claims are recorded in the period incurred.

The Company derives revenue from two primary sources—product revenue and service revenue.

Product revenue consists of shipments of:

•

Diagnostic test kits, dehydrated culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation;

•

Consumable products marketed to veterinarians, retailers, livestock producers and animal health product distributors; and

•

Rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.

Revenues for our products are recognized and invoiced when the product is shipped to the customer.

Service revenue consists primarily of:

•

Genomic identification and related interpretive bioinformatic services; and

•

Other commercial laboratory services.

Revenues for Neogen’s genomics and commercial laboratory services are recognized and invoiced when the applicable laboratory service is performed and the results are conveyed to the customer.

12

Payment terms for products and services are generally 30 to 60 days.

The Company has no contract ~~assets; contract~~assets. Contract liabilities represent deposits made by customers before the satisfaction of performance obligation(s) and recognition of revenue. Upon completion of the performance obligation(s) that the Company has with the customer, the liability for the customer deposit is relieved and revenue is recognized. These customer deposits are ~~listed as~~recorded within Deferred ~~Revenue~~revenue on the condensed consolidated balance sheets.

During the three and nine months ended February 28, 2023, the Company recognized $2.9 million and $8.0 million, respectively of deferred revenue amounts into revenue.

13

On September 1, 2022, Neogen closed on a Reverse Morris Trust transaction to combine with 3M’s Food Safety business. Similar to Neogen, 3M’s former Food Safety business sells diagnostic test kits, dehydrated culture media, and related products used by food producers and processors to detect foodborne bacteria, allergens and levels of general sanitation. Revenue for these products are recognized and invoiced when the product is shipped to the customer. These products are currently manufactured, invoiced, and distributed by 3M on behalf of Neogen under a number of transition service contracts.

The following table presents disaggregated revenue by major product and service categories ~~for~~during the three and ~~six month periods~~nine months ended ~~November 30, 2022~~February 28, 2023 and

~~2021:~~ 2022:


	Three Months Ended February 28,				Nine Months Ended February 28,
(in thousands)	2023		2022		2023		2022
Food Safety
Natural Toxins, Allergens & Drug Residues	$	19,198	$	17,965	$	61,236	$	59,397
Bacterial & General Sanitation		39,444		11,288		91,293		34,709
Culture Media & Other		77,955		18,145		179,293		56,136
Rodent Control, Insect Control & Disinfectants		9,550		9,577		29,502		25,459
Genomics Services		5,395		5,781		16,204		16,909
	$	151,542	$	62,756	$	377,528	$	192,610
Animal Safety
Life Sciences	$	1,440	$	1,339	$	4,456	$	4,011
Veterinary Instruments & Disposables		15,428		17,047		46,534		47,956
Animal Care & Other		8,735		9,449		29,830		29,517
Rodent Control, Insect Control & Disinfectants		20,242		18,359		63,121		58,777
Genomics Services		20,868		19,294		59,168		54,195
		66,713		65,488		203,109		194,456
Total Revenues	$	218,255	$	128,244	$	580,637	$	387,066

Three Months ended November 30,

Six Months ended November 30,

(in thousands)

2022

2021

2022

2021

Food Safety

Natural Toxins, Allergens & Drug Residues
   $ 22,251    $ 21,028    $ 42,038    $ 41,432
Bacterial & General Sanitation
   41,121    12,252    51,849    23,421
Culture Media & Other
   82,084    19,935    101,338    37,981
Rodent Control, Insect Control & Disinfectants
   10,377    8,232    19,952    15,882
Genomics Services
   5,510    5,685    10,809    11,138








   161,343    67,132    225,986    129,854
Animal Safety

Life Sciences
   1,427    1,309    3,016    2,672
Veterinary Instruments & Disposables
   16,433    15,572    31,106    30,909
Animal Care & Other
   10,569    10,849    21,095    20,068
Rodent Control, Insect Control & Disinfectants
   20,665    18,269    42,879    40,418
Genomics Services
   19,596    17,386    38,300    34,901








   68,690    63,385    136,396    128,968








Total Revenues
   $ 230,033    $ 130,517    $ 362,382    $ 258,822

5. NET INCOME (LOSS) PER SHARE

The calculation of net income (loss) per share

follows:


	Three Months Ended February 28,				Nine Months Ended February 28,
(in thousands, except per share amounts)	2023		2022		2023			2022
Numerator for basic and diluted net income (loss) per share:
Net income (loss) attributable to Neogen	$	8,190	$	5,443	$	(28,442	)	$	33,348
Denominator for basic net income (loss) per share:
Weighted average shares		216,218		107,818		179,666			107,648
Effect of dilutive stock options and RSUs		181		315		—			482
Denominator for diluted net income (loss) per share		216,399		108,133		179,666			108,130
Net income (loss) per share:
Basic	$	0.04	$	0.05	$	(0.16	)	$	0.31
Diluted	$	0.04	$	0.05	$	(0.16	)	$	0.31

Note: Due to the net loss during the nine months ended February 28, 2023, the dilutive stock options and RSUs are anti-dilutive.

Three Months Ended
November 30,

Six Months Ended
November 30,

(in thousands, except per share amounts)

2022

2021

2022

2021

Numerator for basic and diluted net income (loss) per share:

Net income (loss) attributable to Neogen
   $ (41,841 )    $ 10,828    $ (36,632 )    $ 27,905
Denominator for basic net income (loss) per share:

Weighted average shares
   216,134    107,641    161,690    107,565
Effect of dilutive stock options and RSUs
   —    481    —    534








Denominator for diluted net income (loss) per share
   $ 216,134    $ 108,122    $ 161,690    $ 108,099
Net income (loss) per share:

Basic
   $ (0.19 )    $ 0.10    $ (0.23 )    $ 0.26
Diluted
   $ (0.19 )    $ 0.10    $ (0.23 )    $ 0.26

~~Note:~~

~~Due to the net loss for the Three and Six month periods end November 30, 2022, the dilutive stock options and RSUs are anti-dilutive for those periods.~~

1

3

6. SEGMENT INFORMATION AND GEOGRAPHIC DATA

We have two reportable segments:

Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits, culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. All new ~~products~~product revenues from the merger of the 3M FSD, effective September 1, 2022, are reported through the Food Safety segment. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product ~~distributors; this~~distributors. This segment also provides genomic identification and related interpretive bioinformatic services. Additionally, the Animal Safety segment produces and markets rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.

Our international operations in the United Kingdom, Mexico, Brazil, China and India originally focused on the Company’s food safety products, and each of these units reports through the Food Safety segment. In recent years, these operations have expanded to offer our complete line of products and services, including those usually associated with the Animal Safety segment, such as cleaners, disinfectants, rodenticides, insecticides, veterinary instruments and genomics services. These additional products and services are managed and directed by existing Food Safety management and are reported through the Food Safety segment.

Neogen’s operation in Australia originally focused on providing genomics services and sales of animal safety products and reports through the Animal Safety segment. With the acquisition of Cell BioSciences in February 2020, this operation expanded to offer our complete line of products and services, including those usually associated with the Food Safety segment. These additional products are managed and directed by existing management at Neogen Australasia and report through the Animal Safety segment.

The accounting policies of each of the segments are the same as those described in Note 1.

Segment information follows:


(in thousands)	Food Safety		Animal Safety		Corporate and Eliminations (1)			Total
As of and during the three months ended February 28, 2023
Product revenues to external customers	$	144,843	$	45,845	$	—		$	190,688
Service revenues to external customers		6,699		20,868		—			27,567
Total revenues to external customers	$	151,542	$	66,713	$	—		$	218,255
Operating income (loss)	$	11,011	$	10,752	$	(6,079	)	$	15,684
Total assets	$	3,975,921	$	349,628	$	183,215		$	4,508,764

As of and during the three months ended February 28, 2022
Product revenues to external customers	$	55,372	$	46,194	$	—		$	101,566
Service revenues to external customers		7,384		19,294		—			26,678
Total revenues to external customers	$	62,756	$	65,488	$	—		$	128,244
Operating income (loss)	$	8,191	$	10,783	$	(12,597	)	$	6,377
Total assets	$	302,605	$	298,854	$	379,746		$	981,205

(in thousands)

Food

Safety

Animal
Safety

Corporate and
Eliminations (1)

Total

As of and for the three months ended November 30, 2022

Product revenues to external customers
   $ 154,223    $ 49,094    $ —      $ 203,317
Service revenues to external customers
   7,120    19,596    —      26,716








Total revenues to external customers
   $ 161,343    $ 68,690    $ —      $ 230,033

Operating income (loss)
   $ 21,446    $ 12,806    $ (41,908 )    $ (7,656 )
Total assets
   $ 3,955,488    $ 329,177    $ 278,577    $ 4,563,242

As of and for the three months ended November 30, 2021

Product revenues to external customers
   $ 60,112    $ 45,999    $ —      $ 106,111
Service revenues to external customers
   7,020    17,386    —      24,406








Total revenues to external customers
   $ 67,132    $ 63,385    $ —      $ 130,517

Operating income (loss)
   $ 10,894    $ 12,701    $ (11,126 )    $ 12,469
Total assets
   $ 298,437    $ 278,994    $ 390,503    $ 967,934

~~(1)~~

(1)

Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities, current and deferred tax accounts and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions.

15


(in thousands)	Food Safety		Animal Safety		Corporate and Eliminations (1)			Total
As of and during the nine months ended February 28, 2023
Product revenues to external customers	$	356,856	$	143,941	$	—		$	500,797
Service revenues to external customers		20,672		59,168		—			79,840
Total revenues to external customers	$	377,528	$	203,109	$	—		$	580,637
Operating income (loss)	$	41,053	$	35,439	$	(62,402	)	$	14,090

As of and during the nine months ended February 28, 2022
Product revenues to external customers	$	171,440	$	140,261	$	—		$	311,701
Service revenues to external customers		21,170		54,195		—			75,365
Total revenues to external customers	$	192,610	$	194,456	$	—		$	387,066
Operating income (loss)	$	29,216	$	36,246	$	(24,871	)	$	40,591

(1)

Includes elimination of intersegment transactions.

14

(in thousands)

Food
Safety

Animal
Safety

Corporate and
Eliminations (1)

Total

As of and for the six months ended November 30, 2022

Product revenues to external customers
   $ 212,013    $ 98,096    $ —      $ 310,109
Service revenues to external customers
   13,973    38,300    —      52,273








Total revenues to external customers

$

225,986    $ 136,396    $ —      $ 362,382

Operating income (loss)
   $ 30,042    $ 24,687    $ (56,323 )    $ (1,594 )

As of and for the six months ended November 30, 2021

Product revenues to external customers
   $ 116,057    $ 94,067    $ —      $ 210,124
Service revenues to external customers
   13,797    34,901    —      48,698








Total revenues to external customers
   $ 129,854    $ 128,968    $ —      $ 258,822

Operating income (loss)
   $ 21,026    $ 25,463    $ (12,275 )    $ 34,214

~~(1)~~

~~Includes elimination of intersegment transactions.~~

The following table presents the Company’s revenue disaggregated by geographic location:


	Three Months Ended February 28,				Nine Months Ended February 28,
(in thousands)	2023		2022		2023		2022
Domestic	$	109,919	$	77,297	$	304,974	$	231,454
International		108,336		50,947		275,663		155,612
Total revenue	$	218,255	$	128,244	$	580,637	$	387,066

Three months ended
November 30,

Six months ended
November 30,

(in thousands)

2022

2021

2022

2021

Domestic
   $ 114,413    $ 76,378    $ 195,055    $ 154,156
International
   115,620    54,139    167,327    104,666








Total revenue
   $ 230,033    $ 130,517    362,382    258,822

7. EQUITY COMPENSATION PLANS

The Company’s long-term incentive plans allow for the grant of various types of share-based awards to key directors, officers and employees of the Company. Incentive and

non-qualified

options to purchase shares of common stock have been granted ~~to directors, officers and employees of Neogen~~ under the terms of the ~~Company’s stock option plans.~~2018 Omnibus Incentive Plan. These options are granted at an exercise price of ~~not less than~~ the ~~fair market value~~closing price of the common stock on the date of grant. Options vest ratably over three and five year periods and the contractual terms are generally five, seven or ten ~~years. A summary~~years. The company grants restricted stock units (RSUs) under the terms of the 2018 Omnibus Incentive Plan, which vest ratably over three and five year periods. The fair value of the RSUs is determined based on the closing price of the common stock ~~option activity during~~on the ~~six months ended November 30, 2022 follows:~~

(options in thousands)

Shares

Weighted-
Average
Exercise Price

Options outstanding June 1, 2022
   3,244    $ 32.13
Granted
   1,687    14.63
Exercised
   (4 )    10.75
Forfeited/Expired
   (592 )    29.75



Options outstanding November 30, 2022
   4,335    $ 25.66

date of grant.

During the three and ~~six month periods~~nine months ended ~~November 30,~~February 28, 2023 and 2022, ~~and 2021,~~ the Company recorded ~~$2,632,000~~$2,812,000 and ~~$1,748,000,~~$1,607,000, and ~~$4,499,000~~$7,311,000 and ~~$3,438,000,~~

$5,045,000, respectively, of expense related to its share-based awards, recorded in general and administrative expense in the condensed consolidated income statement.

15

The weighted-average fair value per share of stock options granted during the first six months of fiscal years 2023 and 2022, estimated on the date of grant using the Black-Scholes option pricing model, was $

~~4.59~~

~~and $~~

~~9.54~~

.

~~The fair value of stock options granted was estimated using the following weighted-average assumptions.~~

FY 2023

FY 2022

Risk-free interest rate
   3.3 % 0.4 %
Expected dividend yield
   0.0 % 0.0 %
Expected stock price volatility
   34.0 % 32.8 %
Expected option life
   4.61 years 3.12 years

~~The company grants restricted stock units (RSUs) to directors, officers and employees under the terms of the 2018 Omnibus Incentive Plan, which vest ratably over~~ ~~three~~ and five year periods. The current units are expensed straight-line over the remaining weighted-average period of 3.2 years. On November 30, 2022 there was $12,820,000 in unamortized compensation cost related to

~~non-vested~~

~~RSUs. A summary of RSU activity during the six months ended November 30, 2022 follows:~~

(RSUs in thousands)

Shares

Weighted-
Average
Fair Value

RSUs outstanding June 1, 2022
   257    $ 36.14
Granted
   584    13.72
Released
   (47 )    37.62
Forfeited/Cancelled
   (5 )    37.63



RSUs outstanding November 30, 2022
   789    $ 19.46

Under the terms of an agreement entered into with 3M as part of the combination of the FSD, the Company issued stock options and RSUs to conveying 3M employees to replace their existing unvested 3M awards under an exchange ratio based on the closing prices of Neogen and 3M common stock on August 31, 2022, the day before the transaction.

These substitute options and RSUs retained their original vesting and expiration terms

~~(originally~~ (originally three year vesting and ten year lives). There were a total of 131,746 substitute options and 29,770 substitute RSUs issued during the second quarter to the conveying

3M employees as part of the employee matters ~~agreement; the~~agreement. The Company recognized

~~$184,000~~

$305,000 and $489,000in compensation expense, ~~(included in the overall compensation expense of~~

$

~~2,632,000~~

)respectively, during the ~~quarter~~three and nine months ended February 28, 2023 for these awards.

The Company offers eligible employees the option to purchase common stock at a 5%5% discount to the lower of the market value of the stock at the beginning or end of each participation period under the terms of the 2021 Employee Stock Purchase ~~Plan; the~~Plan. The discount is recorded in general and administrative expense. Total individual purchases in any year are limited to ~~10%~~10% of compensation.

16

8. BUSINESS COMBINATIONS

The condensed consolidated statements of income (loss) reflect the results of operations for business acquisitions since the respective dates of purchase. All are accounted for using the acquisition method. Goodwill recognized in the acquisitions discussed below relates primarily to enhancing the Company’s strategic platform for the expansion of available product offerings.

On September 17, 2021, the Company acquired all of the stock of CAPInnoVet, Inc., a companion

animal health business that provides pet medications to the veterinary market. This acquisition provides entry into the retail parasiticide market and enhances the Company’s presence in companion animal markets. Consideration for the purchase was net cash of ~~$17.9~~$17.9 million paid at ~~closing, including $150,000 of cash placed in escrow payable to the former owners in 12 months.~~closing. There is also the potential for performance milestone payments to the former owners of up to ~~$6.5~~$6.5 million and the Company could incur up to ~~$14.5~~$14.5 million in future royalty payments. The final purchase allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $308,000, inventory of $531,000, prepayments of $296,000, accounts payable of $120,000, other current liabilities of $84,000,

~~non-current~~

liabilities of $6.5 million (contingent consideration accrual calculated using a Monte Carlo simulation utilizing inputs such as probability and timing of milestone achievements, revenue forecasts and volatility, and estimated discount rates relating to established future cash flowsUpon revaluation of the ~~business), intangible assets~~contingent liability at February 28, 2023, the Company recognized a gain of ~~$19.2 million (with an estimated life of~~

~~15-20~~

~~years) and~~$300,000 on the ~~remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. The $150,000 placed in escrow was paid to the former owners on September 21, 2022.~~performance milestone liability, recorded within other income. The business is operated from our location in Lexington, KY, reporting within the Animal Safety segment.

16

On November 30, 2021, the Company acquired all of the stock of Delf (U.K.) Ltd., a United Kingdom-based manufacturer and supplier of animal hygiene and industrial cleaning products, and Abbott

Analytical Ltd., a related service provider. This acquisition ~~will expand~~expanded the Company’s line of dairy hygiene products and will enhance our cleaner and disinfectant product portfolio. Consideration for the purchase was net cash of ~~$9.5~~$9.5 million paid at closing, including $722,000 of cash placed in escrow payable to the former owner in one year. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $1,059,000, inventory of $972,000, net property, plant and equipment of $152,000, prepayments of $31,000, accounts payable of $497,000, other current liabilities of $378,000,

~~non-current~~

~~deferred tax liabilities of $780,000, intangible assets of $3.1 million (with an estimated life of~~

~~10-15~~

~~years) and the remainder to goodwill~~

~~(non-deductible~~

~~for tax purposes). These values are Level 3 fair value measurements.~~closing. The companies continue to operate from their current location in Liverpool, England, reporting within the Food Safety segment and are managed through Neogen’s Scotland operation.

On December 9, 2021, the Company acquired all of the stock of Genetic Veterinary Sciences, Inc., a companion animal genetic testing business providing genetic information for dogs, cats and birds to animal owners, breeders and veterinarians. This acquisition will further expand the Company’s presence in the companion animal market.

Consideration for the purchase was ~~$11.4~~$11.3 million in net cash. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $38,000, net inventory of $292,000, net property, plant and equipment of $399,000, prepayments of $54,000, accounts payable of $325,000, unearned revenue of $1.9 million, other current liabilities of $321,000, intangible assets of $5.5 million (with an estimated life of

~~5-15~~

~~years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements.~~ The business is operated from its current location in Spokane, Washington, reporting within the Animal Safety segment.

Since completion of initial estimates in the second quarter of fiscal year 2022, the Company has recorded insignificant measurement period adjustments, which resulted in a decrease to the base purchase price.

On July 1, 2022, Neogen acquired all of the stock of

Thai-Neo

Biotech Co., Ltd., a longstanding distributor of Neogen’s food safety products to Thailand and Southeast Asia. This acquisition gives Neogen a direct sales presence in Thailand. Consideration for the purchase was ~~$1,581,000~~$1,581,000 in net cash, with ~~$1,310,000~~$1,310,000 paid at closing, ~~$37,000~~$37,000 paid on November 29, 2022 as a working capital adjustment and ~~$234,000~~$234,000 payable on October 1, 2023. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of ~~$177,000,~~$177,000, inventory of ~~$232,000,~~$232,000, prepaids of ~~$3,000,~~$3,000, net property, plant and equipment of ~~$16,000,~~$16,000, other

non-current

assets of ~~$6,000,~~$6,000, accounts payable of ~~$98,000,~~$98,000, other payables of ~~$6,000,~~

$6,000, non-current

tax liabilities of ~~$124,000,~~$124,000, intangible assets of ~~$620,000~~$620,000 (with an estimated life of 10 years) and the remainder to goodwill

~~(non-deductible~~

(non-deductible for tax purposes). The business continues to operate in Bangkok, Thailand, reporting within the Food Safety segment.

17

On February 10, 2023, Neogen acquired certain assets as part of an asset purchase agreement with Corvium, Inc., a partner and supplier within the Company's software analytics platform. This acquisition, which primarily includes the software technology, advances the Company's food safety data analytics strategy. The purchase price consideration was $24.1 million, which included certain amounts for litigation and indemnity escrow. There is also the potential for performance milestone payments based on the successful implementation of the software service at customer sites and sale of licenses. As a result, the Company has recorded contingent liabilities as part of the opening balance sheet within Other accruals and Other non-current liabilities, as shown below. As of February 28, 2023, the Company has recorded a preliminary allocation of the purchase consideration to assets acquired and liabilities assumed based on initial fair value estimates and is subject to continuing management analysis, with assistance from third party valuation advisors. Goodwill, which is fully deductible for tax purposes, includes value associated with profits earned from data management solutions that can be offered to existing customers and the expertise and reputation of the assembled workforce and developed software technology. These values are Level 3 fair value measurements. The preliminary fair values of net tangible assets and intangible assets acquired were based on preliminary valuations prior to receiving a third-party assessment, and our estimates and assumptions are subject to change within the measurement period (up to one year from the acquisition date). The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.

Due to the Company's acquisition of Corvium, Inc., it recorded a loss of $1.5 million in the third quarter on dissolution of its minority interest in that company.

The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the date of acquisition:


(in thousands)
Prepaids and other current assets	$	101
Property, plant and equipment		13
Intangible assets		14,000
Deferred revenue		(1,827	)
Other accruals		(1,000	)
Adjustment of annual license prepaid		(419	)
Other non-current liabilities		(1,000	)
Total identifiable assets and liabilities acquired		9,868
Goodwill		14,199
Total purchase consideration	$	24,067

For each completed acquisition listed above, the revenues and net income were not considered material and were therefore not disclosed.

3M Food Safety transaction

On September 1, 2022, Neogen, 3M Company (“3M”), and Garden SpinCo Corporation (“Garden SpinCo”), a newly formed, wholly owned subsidiary of 3M created to carve out 3M’s Food Safety Division (“3M FSD”, “FSD”), closed on the transaction combining 3M’s FSD with Neogen in a Reverse Morris Trust transaction and Garden SpinCo became a

wholly owned

subsidiary of Neogen (“FSD transaction”). Following the FSD transaction,

pre-merger

Garden SpinCo stockholders own, in the aggregate, ~~approxim~~

~~ately~~

~~50.1%~~approximately 50.1% of the issued and outstanding shares of Neogen common stock and

pre-merger

Neogen shareholders own, in the aggregate, approximately ~~49.9%~~49.9% of the issued and outstanding shares of Neogen common stock. This transaction is a business combination and ~~will be~~was accounted for using the acquisition method.

18

The acquired business is a leading provider of food safety testing solutions. It offers a broad range of food safety testing products that support multiple industries within food and beverage, helping producers to prevent and protect consumers from foodborne illnesses. The business has a broad global presence with products used in more than 60 countries and a diversified revenue base of more than 100,000

end-user

customers. The combination of Neogen and the 3M FSD creates a leading innovator with an enhanced geographic footprint, innovative product offerings, digitization capabilities, and financial flexibility to capitalize on robust growth trends in sustainability, food safety, and supply chain integrity. The acquired Food Safety business continues to primarily operate in facilities in Minnesota and the United Kingdom, and is being managed overall in Michigan, reporting within the Food Safety segment.

The purchase price consideration for the 3M FSD was

~~$3.2~~ $3.2 billion, net of customary purchase price adjustments and transaction costs, which consisted of 108,269,946 shares of Neogen common stock issued on closing with a fair value of ~~$2.3~~$2.2 billion and cash consideration of $1

$1billion, funded by the additional financing secured by the Company.

See Note 10 ~~– Long Term~~

~~Debt~~ for further detail on the debt incurred.

17

~~Table of Contents~~

~~As of November 30, 2022,~~

During the three months ended February 28, 2023, the Company ~~has~~ recorded aadjustments to its preliminary allocation of the purchase consideration to assets acquired and liabilities assumed based on initial fair value estimates and is subject to continuing management analysis, with assistance from third party valuation advisors. In the third quarter of fiscal 2023, net working capital adjustments resulted in changes to the inventories acquired and valuations of property, plant and equipment resulted in recognizing the fair value of assets acquired. The excess of the purchase price over the fair value of the net tangible assets and identifiable intangible assets

of $

~~1.96~~

1.98billion was recorded as goodwill, of which ~~$1.90~~$1.92 billion is not deductible for tax purposes. Goodwill, which increased in the third quarter of fiscal 2023 based on an updated purchase consideration, includes value associated with profits earned from market and expansion capabilities, expected synergies from integration and streamlining operational activities, the expertise and reputation of the assembled workforce and other intangible assets that do not qualify for separate recognition. These values are Level 3 fair value measurements.

The preliminary fair values of net tangible assets and intangible assets acquired were based on preliminary valuations, and our estimates and assumptions are subject to change within the measurement period (up to one year from the acquisition date). The ~~final determination may result in asset~~primary areas of the preliminary purchase price allocation that are not yet finalized relate to the fair value of inventories and ~~liability~~property, plant and equipment, as well as deferred income tax liabilities. The fair values of the assets acquired and ~~tax bases that differ from the~~liabilities assumed are based on our preliminary estimates and ~~require changes~~assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. While we believe that these preliminary estimates provide a reasonable basis for estimating the fair value of the assets acquired and liabilities assumed, we will continue to evaluate available information prior to finalization of the ~~preliminary amounts recognized.~~

amounts.

The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the date of acquisition:


(in thousands)
Cash and cash equivalents	$	319
Inventories		18,403
Other current assets		14,855
Property, plant and equipment		25,721
Intangible assets		1,560,000
Right of use asset		882
Lease liability		(885	)
Deferred tax liabilities		(355,347	)
Other liabilities		(3,585	)
Total identifiable assets and liabilities acquired		1,260,363
Goodwill		1,978,149
Total purchase consideration	$	3,238,512

19

(in thousands)

Cash and cash equivalents

$
319
Inventories
   21,402
Other current assets
   14,855
Property, plant and equipment
   20,010
Intangible assets
   1,560,000
Right of use asset
   882
Lease liability
   (885 )
Deferred tax liabilities
   (353,760 )
Other liabil
i
ties
   (3,584 )


Total identifiable assets and liabilities acquired
   1,259,239
Goodwill
   1,963,171


Total purchase consideration
   $ 3,222,410

The following table summarizes the intangible assets acquired and the useful life of these assets.


(in thousands)	Fair Value		Useful Life in Years
Trade Names and Trademarks	$	110,000		25
Developed Technology		280,000		15
Customer Relationships		1,170,000		20
Total intangible assets acquired	$	1,560,000

(in thousands)

Fair Value

Useful Life in Years

Trade Names and Trademarks
   $ 120,000    25
Developed Technology
   280,000    15
Customer Relationships
   1,160,000    20



Total intangible assets acquired
   $ 1,560,000

~~For~~

During the three and ~~six~~nine months ended ~~November 30, 2022,~~February 28, 2023, transaction ~~costs~~fees and integration expenses of ~~$39.1~~$2.8 million and ~~$52.9~~$55.6 million, respectively, were ~~expensed; in~~expensed. In the ~~prior year second quarter,~~three and nine months ended February 28, 2022, acquisition related costs of ~~$9.3~~$10.6 million and $19.9 million were ~~expensed.~~expensed, respectively. These costs are included in general and administrative expenses in the Company’s condensed consolidated statements of income

(loss)

.

The operating results of the 3M FSD have been included in the Company’s condensed consolidated statements of income

(loss)

since the acquisition date. In the ~~second~~third quarter of fiscal 2023, the 3M FSD’s total revenue

was

~~$92.7~~ $87.0 million and operating ~~loss~~income was approximately ~~$29.7~~$3.3 million. The operating ~~loss~~income includes ~~$39.1~~$2.8 million of transaction ~~costs, $20.3~~fees and integration expenses, $20.3 million of amortization expense for acquired intangible assets and ~~$3.9 million of~~a $614,000 credit to cost of goods sold related to an adjustment to the step up to fair value on acquired inventory.

The following table presents pro forma information as if the merger with the 3M FSD business had occurred on June 1, 2021 and had been combined with the results reported in our condensed consolidated statements of income

(loss)

for all periods presented:


	Three Months Ended February 28,					Nine Months Ended February 28,
(in thousands, unaudited)	2023		2022			2023			2022
Net sales	$	218,300	$	219,900		$	675,600		$	668,100
Operating Income (loss)	$	15,700	$	(17,000	)	$	(5,400	)	$	(10,900	)

   Three Months Ended    Six Months Ended
   November 30,    November 30,
in thousands, unaudited
   2022    2021    2022    2021
Net sales
   $ 230,033    $ 225,700    $ 457,300    $ 448,200
Operating Income (loss)
   $ (7,700 )    $ (1,600 )    $ (21,100 )    $ 6,100

The unaudited pro forma information is presented for informational purposes only and is not indicative of the results that would have been achieved if the merger had taken place at such time. The unaudited pro forma information presented above includes adjustments primarily for amortization charges for acquired intangible assets and certain acquisition-related expenses for legal and professional fees.

In connection with the acquisition of the 3M FSD, the Company and 3M entered into several transition service agreements, including manufacturing, distribution and certain back-office support, that have been accounted for separately from the acquisition of assets and assumption of liabilities in the business combination. 3M periodically remits amounts charged to customers on our behalf and charges us for the associated cost of goods sold and ~~transitions~~transition service fees. As of ~~November 30, 2022,~~February 28, 2023, a net receivable from 3M of

~~$36.5~~

$42.9million was included in ~~Prepaid~~prepaid expenses and other current assets in the Company’s condensed consolidated balance sheets.

18

20

~~Table of Contents~~

9. GOODWILL AND INTANGIBLE ASSETS

The following table summarizes goodwill by reportable segment:


(in thousands)	Food Safety			Animal Safety			Total
May 31, 2022	$	67,558		$	75,146		$	142,704
Acquisitions(1)		1,989,270			6,754			1,996,024
Impairment (2)		(1,300	)		—			(1,300	)
Foreign currency translation and other		(1,984	)		(326	)		(2,310	)
February 28, 2023	$	2,053,544		$	81,574		$	2,135,118

(1)

Animal Safety acquisitions represents portion of 3M Food Safety transaction recorded at Neogen Australasia.

(2)

Impairment during the nine months ended February 28, 2023 relates to discontinued product lines. The amount was determined based on a relative fair value basis of the product lines compared to the overall reporting unit.

(in thousands)

Food Safety

Animal Safety

Total

May 31, 2022
   $ 67,558    $ 75,146    $ 142,704
Acquisitions
(1)
   1,957,810    6,115    $ 1,963,925
Foreign currency translation and other
   16,058    (290 )    $ 15,768






November 30, 2022
   $ 2,041,426    $ 80,971    $ 2,122,397

~~(1)~~

~~Animal Safety acquisitions represents portion of 3M Food Safety transaction recorded at Neogen Australasia.~~

~~At November 30, 2022,~~

As of February 28, 2023, non-amortizable intangible assets included licenses of ~~$569,000,~~$569,000, trademarks of ~~$13,423,000~~$12,459,000 and other intangibles of ~~$1,224,000. At~~$1,224,000. During the three and nine months ended February 28, 2023, the Company recorded an impairment of $1.0 million to its non-amortizable trademarks related to discontinued product lines.

As of May 31, 2022, non-amortizable intangible assets included licenses of ~~$569,000,~~$569,000, trademarks of ~~$13,604,000~~$13,604,000 and other intangibles of ~~$1,224,000.~~

$1,224,000.

Amortizable intangible assets consisted of the following and are included in customer-based intangibles and other non-current assets within the condensed consolidated balance sheets:


(in thousands)	Gross Carrying Amount		Less Accumulated Amortization		Net Carrying Amount
Licenses	$	17,401	$	6,952	$	10,449
Covenants not to compete		782		716		66
Patents		8,670		5,045		3,625
Customer relationships		1,245,875		65,764		1,180,111
Trade names and trademarks		111,167		2,453		108,714
Developed technology		311,350		13,198		298,152
Other product and service-related intangibles		27,530		8,418		19,112
February 28, 2023	$	1,722,775	$	102,546	$	1,620,229

Licenses	$	17,109	$	5,682	$	11,427
Covenants not to compete		846		671		175
Patents		8,347		4,583		3,764
Customer relationships		75,000		33,662		41,338
Trade names and trademarks		1,180		167		1,013
Developed technology		17,741		6,124		11,617
Other product and service-related intangibles		27,299		4,527		22,772
May 31, 2022	$	147,522	$	55,416	$	92,106

(in thousands)

Gross
Carrying
Amount

Less
Accumulated
Amortization

Net
Carrying
Amount







Licenses
   $ 16,979    $ 6,394    10,585
Covenants not to compete
   371    234    137
Patents
   8,029    4,565    3,464
Customer relationships
   1,234,202    49,735    1,184,467 ��
Trade names and trademarks
   121,135    1,417    119,718
Developed technology
   296,897    11,000    285,897
Other product and service-related intangibles
   26,947    4,701    22,245






November 30, 2022
   $ 1,704,560    $ 78,046    $ 1,626,514






Licenses
   $ 17,109    $ 5,682    $ 11,427
Covenants not to compete
   846    671    175
Patents
   8,347    4,583    3,764
Customer relationships
   75,000    33,662    41,338
Trade names and trademarks
   1,180    167    1,013
Developed technology
   17,741    6,124    11,617
Other product and service-related intangibles
   27,299    4,527    22,772






May 31, 2022
   $ 147,522    $ 55,416    $ 92,106

Amortization expense relating to

de

~~finite-lived~~ definite-lived intangible assets was ~~$22.7~~$22.9 million and ~~$2.4~~$2.6 million ~~for~~during the three months ended ~~November 30,~~February 28, 2023 and 2022, ~~and 2021,~~ respectively, and ~~$25.1~~$48.0 million and ~~$4.6~~$7.3 million ~~for~~during the ~~six~~nine months ended ~~November 30,~~February 28, 2023 and 2022, ~~and 2021,~~ respectively.

The estimated amortization expense for each of the five succeeding fiscal years is as follows: ~~$45.6~~$23.1 million remaining in 2023, ~~$90.8~~$91.8 million in 2024, ~~$90.3~~$91.3 million in 2025, ~~$90.2~~$91.2 million in 2026 and ~~$89.7~~$90.7 million in 2027 and ~~$1.22~~$1.23 billion thereafter.

21

The amortizable intangible assets useful lives are 2 to 20 years for licenses, 3 to 10 years for covenants not to compete, 5 to 25 years for patents, 9 to 20 years for customer relationships, 10 to 25 years for trade names and trademarks, 10 to 20 years for developed technology and 5 to 15 years for other product and service-related intangibles. All definite-lived intangibles are amortized on a straight-line basis with the exception of definite-lived customer-based intangibles and product and service-related intangibles, which are amortized on either a straight-line or an accelerated basis.

The weighted average remaining amortization period for intangibles was 18 years ~~at November 30, 2022~~ as of February 28, 2023 and eight years at as of May 31, 2022.

19

~~Table of Contents~~

10

.

10. LONG TERM DEBT

The Company’s long-term debt consists of the following:


(in thousands)	February 28, 2023
Term Loan	$	550,000
Senior Notes		350,000
Total long-term debt		900,000
Less: Unamortized debt issuance costs		(15,299	)
Total non-current debt, net	$	884,701

(in thousands)
   As of
November 30, 2022    As of
May 31, 2022
Term Loan
   $ 590,000    $ —
Senior Notes
   350,000    —




Total long-term debt
   $ 940,000    $ —
Less: Unamortized debt issuance costs
   (16,038 )    —




Total
non-current
debt, net
   $ 923,962    $ —

The Company had a financing agreement with a bank providing for a ~~$15.0~~$15.0 million unsecured revolving line of credit, which originally expired on November 30, 2023, but was replaced by the five-year senior secured revolving facility as part of the Credit Facilities described below. There were no advances against the line of credit during fiscal 2022 and there were no advances in fiscal 2023 before the line of credit was extinguished. Interest on any borrowings under that agreement was at LIBOR plus 100 basis ~~points.~~points. Financial covenants included maintaining specified levels of tangible net worth, debt service coverage, and funded debt to EBITDA, each of which the Company was in compliance with during the period the line of credit was available.

As of May 31, 2022, the Company had no outstanding debt. In connection with the acquisition of 3M’s Food Safety business as described more fully in Note 8, Neogen incurred financing through Garden SpinCo as follows:

Credit Facilities

On June 30, 2022, Garden SpinCo entered into a credit agreement consisting of a five-year senior secured term loan facility (“term loan facility”) in the amount of ~~$650~~$650 million and a five-year senior secured revolving facility (“revolving facility”) in the amount of ~~$150~~$150 million (collectively, the “Credit Facilities”) to fund the 3M Food Safety transaction. The term loan facility was drawn on August 31, 2022, to fund the closing of the 3M Food Safety transaction on September 1, 2022 while the revolving facility remained undrawn and continues to be undrawn as of ~~November 30, 2022.~~

February 28, 2023.

The Credit Facilities bear interest based on the term SOFR plus an applicable margin between a range of 150 to 225 basis points determined for each interest period and paid monthly. ~~For~~During the three and ~~six~~nine months ended ~~November 30, 2022,~~February 28, 2023, the interest rates ranged from ~~4.80%~~6.48% to ~~6.08%~~

6.66% per ~~annum.~~annum and 4.80% to 6.66% per annum, respectively. The term loan facility matures

on June 30, 2027 and the revolving facility matures at the earlier of June 30, 2027 and the termination of the revolving commitments.

In ~~addition,~~November 2022, the Company entered into an interest rate swap agreement, whereby interest on $250 million of the total $550 million principal balance is paid at a fixed rate. See Note 13. "Derivatives"for further detail on the swap agreement.

22

The term loan facility contains an optional prepayment feature at the discretion of the Company. The Company determined that the prepayment feature did not meet the definition of an embedded derivative and does not require bifurcation from the host liability and, accordingly, has accounted for the entire instrument at amortized cost. In accordance with the prepayment feature, the Company paid ~~$60~~$60 million of the term loan facility’s principal in September 2022 ~~prior~~and an additional $40 million of the term loan facility's principal in December 2022, in order to decrease the ~~first scheduled quarterly repayment.~~

outstanding debt balance.

The Company can ~~at its sole discretion,~~ draw any amount under the revolving facility up to the $150 million limit, with the amount to be repaid on the termination date of the revolving commitments. Debt issuance costs of ~~$2.4~~$2.4 million

were incurred related to the revolving facility. These costs are being amortized as interest expense in the condensed consolidated statements of income (loss) over the contractual life of the revolving facility using the straight line method. Amortization of the deferred debt issuance costs for the revolving facility

was ~~$122,000 for~~

$122,000 and $244,000 during the three and ~~six month periods~~nine months ended ~~November 30, 2022.~~February 28, 2023, respectively. Debt issuance costs of ~~$489,000~~$489,000 were recorded in Prepaid expenses and other current assets and ~~$1.8~~$1.6 million were recorded in Other non-current assets on the condensed consolidated balance sheet ~~at November 30, 2022.~~as of February 28, 2023. The Company must pay an annual commitment fee ranging

from

0.20

% and

0.35

% on the unused portion of the Revolving Credit Facility, paid quarterly. As of ~~November 30, 2022,~~February 28, 2023, the commitment fee was

0.35

% and $

~~225,000~~

131,000 and $356,000was recorded as interest expense in the

condensed consolidated statements of income (loss) ~~for~~during the

three and ~~six~~nine months ended ~~November 30, 2022.~~

~~Total~~February 28, 2023, respectively.

There was no accrued interest payable on the term loan ~~was $~~

~~3.0~~

~~million~~ as of ~~November 30, 2022 based on the term SOFR interest rate of~~

~~6.08~~

~~% and included in current liabilities on the consolidated balance sheets.~~February 28, 2023. The Company incurred ~~$10.2~~

$10.2million in total debt issuance costs on the term loan which is recorded as an offset to the term loan facility and amortized over the contractual life of the loan to interest expense using the straight line method. The amortization of deferred debt issuance costs

of $

529,000

and $1.1 million and interest expense of $

~~8.5~~

9.1 million and $17.4 million (excluding swap credit of $136,000) for the term loan was

included in the condensed consolidated statements of income (loss) ~~for~~during the

three and ~~six~~nine months ended ~~November 30, 2022.~~

February 28, 2023, respectively.

Financial covenants include maintaining specified levels of funded debt to EBITDA, and debt service coverage. ~~At November 30, 2022,~~As of February 28, 2023, the Company was in compliance with its debt covenants.

20

~~Table of Contents~~

Senior Notes

On July 20, 2022, Garden SpinCo closed on an offering of ~~$350~~$350 million aggregate principal amount of ~~8.625%~~8.625% senior notes due 2030

(the “Notes”) in a private placement at par. The Notes were initially issued by Garden SpinCo to 3M and were transferred and delivered by 3M to the selling securityholder in the offering, in satisfaction of certain of 3M’s existing debt. Upon closing of the 3M Food Safety transaction on September 1, 2022, the Notes became guaranteed on a senior unsecured basis by the Company and certain wholly-owned domestic subsidiaries of the Company.

The Company determined that the redemption features of the Notes did not meet the definition of a derivative and thus does not require bifurcation from the host liability and accordingly has accounted for the entire instrument at amortized cost.

Total accrued interest on the Notes was ~~$11.0~~$3.4 million as of ~~November 30, 2022~~February 28, 2023 based on the stated interest rate of ~~8.625%~~8.625% and included in current liabilities on the condensed consolidated balance sheets. The Company incurred total debt issuance costs of ~~$6.7~~$6.7 million which is recorded as an offset to the Notes and amortized over the contractual life of the Notes to interest expense using the

straight line

method. ~~For~~During the three and ~~six~~nine months ended ~~November 30, 2022,~~February 28, 2023, the Company recorded ~~$11.0~~$7.8 million and $19.1 million of interest expense for the Notes in the

condensed consolidated statements of income (loss), of

which ~~$348,000~~$209,000 and $557,000 related to the amortization of deferred debt issuance ~~costs.~~

costs, respectively.

23

There are no required principal payments through fiscal year 2026, due to $100 million in prepayments made in fiscal 2023.The expected maturities associated with the Company’s outstanding debt as of ~~November 30, 2022,~~February 28, 2023, were as follows:


(in thousands)	Amount
Fiscal Year
Remainder of 2023	$	—
2024		—
2025		—
2026		—
2027		34,063
Thereafter		865,937
Total	$	900,000

(in thousands)
   Amount
Fiscal Year

Remainder of 2023
   $ —
2024
   —
2025
   —
2026
   29,375
2027
   44,688
Thereafter
   865,937


Total
   $ 940,000

1

.

11. INCOME TAXES

Income tax benefit was $10.5 million during the three months ended February 28, 2023, and income tax expense was $1.2 million during the three months ended February 28, 2022. Income tax benefit was $1.3 million during the nine months ended February 28, 2023 and income tax expense was $8.0 million during the nine months ended February 28, 2022. Income tax benefit in the ~~second~~third quarter of fiscal 2023 ~~was $7.8 million, compared~~is primarily related to ~~$2.1 million~~a decrease in pre-tax income used to calculate the ~~same period of the prior year; for the year to date,~~annualized effective tax rate. The net income tax ~~expense was $9.2 million, compared to $6.8 million in fiscal 2022. Income tax expense in the second quarter of fiscal 2023~~benefit amount also includes approximately ~~$6.7~~$1.1 million of expense related to

non-deductible

transaction costs associated with the 3M Food Safety ~~transaction and $625,000~~

~~of expense due to an increase in our state rate for deferred tax liabilities. In each comparative period, there was minimal benefit from the exercise of stock options.~~

transaction.

The total amounts of unrecognized tax benefits that, if recognized, would affect the effective tax rate as of ~~November 30, 2022~~February 28, 2023 and May 31, 2022 are ~~$1.4~~$1.5 million and ~~$808,000~~

$808,000, respectively. The increase in unrecognized tax benefits is primarily associated with the acquired 3M FSD, including positions for transfer pricing and research and development credits.

2

1

~~Table of Contents~~

1

2

.

12. COMMITMENTS AND CONTINGENCIES

The Company is involved in environmental remediation and monitoring activities at its Randolph, Wisconsin manufacturing facility and accrues for related costs when such costs are determined to be probable and estimable. The Company currently utilizes a pump and treat remediation strategy, which includes semi-annual monitoring and reporting, consulting, and maintenance of monitoring wells. We expense these annual remediation costs, ~~of remediation,~~ which have ranged from ~~$38,000~~$38,000 to ~~$131,000~~$131,000 per year over the past five years. The Company’s estimated remaining liability for these costs ~~was $916,000 at~~are $916,000 as of both ~~November 30, 2022~~February 28, 2023 and May 31, 2022, measured on an undiscounted basis over an estimated period of 15 ~~years.~~years. In fiscal 2019, the Company performed an updated Corrective Measures Study on the site, per a request from the Wisconsin Department of Natural Resources (WDNR) and is currently in discussion with the WDNR regarding potential alternative remediation strategies going forward. The Company believes that the current pump and treat strategy is appropriate for the site. However, the Company has undertaken a pilot study in which chemical reagents ~~are~~were injected into the ground in an attempt to reduce

on-site

contamination. At this time, the outcome of the pilot study is unknown, but a change in the current remediation strategy, depending on the alternative selected, could result in an increase in future costs and ultimately, an increase in the currently recorded liability, with an offsetting charge to operations in the period recorded. The Company has recorded ~~$100,000~~$100,000 as a current liability ~~at November 30, 2022,~~as of February 28, 2023, and the remaining ~~$816,000~~$816,000 is recorded in other

non-current

liabilities in the condensed consolidated balance sheets.

24

On March 6, 2020, the Company received an administrative subpoena from the U.S. Treasury Department’s Office of Foreign Assets Control (OFAC) regarding activities or transactions involving parties located in Iran. The Company subsequently conducted an internal investigation under the direction of outside legal counsel and disclosed information concerning certain genomic testing services provided to an unrelated U.S.-based party engaged in veterinary activities involving an Iranian party. The Company continues to cooperate with OFAC’s investigation and is currently examining whether certain of these activities may be eligible for OFAC General Licenses authorizing agricultural and veterinary activities.

In addition to responding to the administrative subpoena, the Company has implemented additional compliance measures to prevent inadvertent dealings with restricted countries or parties. These measures will further enhance the Company’s international trade compliance program, which is designed to assure that the Company does not conduct business directly or indirectly with any countries or parties subject to U.S. economic sanctions and export control laws. Although it is too early to predict what action, if any, that OFAC will take, the Company does not currently have any reason to believe that OFAC’s pending investigation will have a material impact on its operations, the results of operations for any future period, or its overall financial condition. In fiscal 2020, the Company took a charge to Other expense and recorded a reserve of $

600,000 to provide for potential fines or penalties on this matter. At this time, the Company believes that it is adequately reserved for this issue.

The Company is subject to certain legal and other proceedings in the normal course of business that, in the opinion of management, should not have a material effect on its future results of operations or financial position.

1

3

.

13. DERIVATIVES

We operate on a global basis and are exposed to the risk that our financial condition, results of operations and cash flows could be adversely affected by changes in foreign currency exchange ~~rates.~~rates and changes in interest rates. To reduce the potential effects of foreign currency exchange rate movements on net earnings, we enter into derivative financial instruments in the form of foreign currency exchange forward contracts with major financial institutions and have also entered into interest rate swap contracts as a hedge against changes in interest rates. ~~All derivatives~~Derivatives are ~~recognized as~~recorded at fair value in other current assets, orother assets, accrued liabilities and ~~measured at fair value.~~other long-term liabilities. Derivatives that are not determined to be effective hedges are adjusted to fair value with a corresponding adjustment to earnings. We do not use financial instruments for trading or speculative purposes.

22

Derivatives Not Designated as Hedging Instruments

We forecast our net exposure in various receivables and payables to fluctuations in the value of various currencies, and have entered into a number of foreign currency forward contracts each month to mitigate that exposure. These contracts are recorded net at fair value on our condensed consolidated balance sheets, classified as Level 2 in the fair value ~~hierarchy; gains~~hierarchy. Gains and losses from these contracts ~~were~~are recognized in other income in our condensed consolidated statements of income (loss). The notional amount of forward contracts in place was ~~$150.2~~$18.5 million and ~~$4.4~~$4.4 million as of ~~November 30, 2022~~February 28, 2023 and May 31, 2022, ~~respectively; the increase is the result~~respectively, and consisted of ~~a number~~hedges of ~~intercompany loans entered into by our international operations as a result of the 3M Food Safety business combination.~~transactions up to April 2023.


(in thousands)
Fair Value of Derivatives Not Designated as Hedging Instruments	Balance Sheet Location	November 30, 2022			May 31, 2022			Balance Sheet Location	February 28, 2023		May 31, 2022
Foreign currency forward contracts, net	Other accruals	$	(9,708	)	$	(78	)	Other accruals	$	162	$	(78	)

25

The location and amount of gains (losses) from derivatives not designated as hedging instruments in our condensed consolidated statements of income (loss) were as follows:


		Three months ended						Three months ended
(in thousands) Derivatives Not Designated as Hedging Instruments	Location in statements of income (loss)	November 30, 2022			November 30, 2021		Location in statements of income (loss)	February 28, 2023			February 28, 2022
Foreign currency forward contracts	Other income (expense)	$	(9,128	)	$	492	Other (expense) income	$	(1,564	)	$	(363	)

		Six months ended
(in thousands) Derivatives Not Designated as Hedging Instruments	Location in statements of income (loss)	November 30, 2022			November 30, 2021
Foreign currency forward contracts	Other income (expense)	$	(8,248	)	$	1,011


		Nine months ended
(in thousands) Derivatives Not Designated as Hedging Instruments	Location in statements of income (loss)	February 28, 2023			February 28, 2022
Foreign currency forward contracts	Other (expense) income	$	(9,812	)	$	648

Derivatives Designated as Hedging Instruments

In November 2022, we entered into a receive-variable, pay-fixed interest rate swap agreement with an initial $250 million notional value, which is designated as a cash flow ~~hedge, which has a $250 million notional value.~~hedge. This agreement fixed a portion of the variable interest due on our term loan facility, with an effective date of December 2, 2022 and a maturity date of June 30, ~~2027.~~2027. Under the terms of the agreement, we pay a fixed interest rate of ~~4.215%~~6.215% (4.215% rate and 2.00% margin) and receive a variable rate of interest based on term SOFR from the counterparty, which is reset according to the duration of the SOFR term. The fair value of the interest rate swap as of ~~November 30, 2022~~February 28, 2023 was ~~($3.2) million.~~$714,000.

We record the fair value of our interest rate swaps on a recurring basis using Level 2 observable market inputs for similar assets or liabilities in active markets.



(in thousands) Fair Value of Derivatives Designated as Hedging Instruments	Balance Sheet Location	November 30, 2022		May 31, 2022		Balance Sheet Location	February 28, 2023			May 31, 2022
Interest rate swaps – current						Other current assets	$	2,689		$	-
Interest rate swaps – non-current	Other non-current liabilities	$	3,153	$	—	Other non-current liabilities		(1,975	)		-

The ~~impacts~~following table summarizes the other comprehensive income (loss) before reclassifications of ~~our~~pre-tax derivative ~~instruments on~~gains and losses:


(in thousands)	Other Comprehensive Income Before Reclassifications During
	Three months ended				Nine months ended
Derivatives Designated as Hedging Instruments	February 28, 2023		February 28, 2022		February 28, 2023		February 28, 2022
Interest rate swaps	$	3,083	$	—	$	655	$	—

The following table summarizes the ~~accompanying Consolidated Statements~~reclassification of ~~Comprehensive Income (Loss) for the three~~pre-tax derivative gains and ~~six months ended November 30, 2022 and November 30, 2021 were as follows:~~losses into net income from accumulated other comprehensive income (loss):


(in thousands)	Location in statements of comprehensive income (loss)	Three months ended				Six months ended					Gain (Loss) Reclassified During
	Location in statements of comprehensive income (loss)										Three months ended				Nine months ended
Derivatives Designated as Hedging Instruments	Location in statements of comprehensive income (loss)	November 30, 2022		November 30, 2021		November 30, 2022		November 30, 2021		Location of Gain (Loss) Reclassified	February 28, 2023		February 28, 2022		February 28, 2023		February 28, 2022
Interest rate swaps	Location in statements of comprehensive income (loss)	$	(2,428)	$	—	$	(2,428)	$	—	Interest expense	$	105	$	—	$	105	$	—

23

26

PART I – FINANCIAL INFORMATION

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The information in this Management’s Discussion and Analysis of Financial Condition and Results of Operations contains both historical financial information and forward-looking statements. Neogen does not provide forecasts of future financial performance. While management is optimistic about the Company’s long-term prospects, historical financial information may not be indicative of future financial results.

Safe Harbor and Forward-Looking Statements

Forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are made throughout this Quarterly Report on Form 10-Q. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors, including competition, recruitment including circumstances beyond our control at our transition manufacturing partner, retention and dependence on key employees, impact of weather on agriculture and food production, effects of the ongoing COVID-19 pandemic on our business, global business disruption caused by the Russia invasion in Ukraine and related sanctions, identification and integration of acquisitions, research and development risks, patent and trade secret protection, government regulation and other risks detailed from time to time in the Company’s reports on file at the Securities and Exchange Commission, that could cause Neogen Corporation’s results to differ materially from those indicated by such forward-looking statements, including those detailed in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

In addition, any forward-looking statements represent management’s views only as of the day this Quarterly Report on Form 10-Q was first filed with the Securities and Exchange Commission and should not be relied upon as representing management’s views as of any subsequent date. While management may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its views change.

TRENDS AND UNCERTAINTIES

During fiscal 2022 and throughout the ~~first six~~nine months ~~of fiscal~~ended February 28, 2023, we ~~have~~ experienced higher than ~~expected~~normal input cost inflation, including ~~higher~~increases in transportation, supply chain and labor costs, that have negatively impacted operating results. International freight costs, particularly for containers originating in Asia with an ultimate destination in the United States, have eased ~~somewhat in the first half of~~during fiscal 2023, ~~although not~~in some instances returning to ~~pre-2022~~pre-pandemic levels. Pricing actions taken during fiscal 2022 and the ~~first six~~nine months ~~of fiscal~~ended February 28, 2023 ~~have~~ mitigated some, but not all of the inflationary pressures. Ongoing inflation may also have an impact on our customer’s purchasing decisions and order patterns. We estimate inflation will continue to affect us in the remainder of fiscal 2023, although at this time, it is impracticable to quantify the impact.

Although we have no operations in or direct exposure to Russia, Belarus and Ukraine, we have experienced intermittent shortages in materials and increased costs for transportation, energy and raw materials due, in part, to the negative impact of the Russia-Ukraine military conflict on the global economy. ~~To date, our~~Our European operations and customer base have ~~not~~ been ~~materially~~adversely impacted by the ~~conflict, however,~~conflict. However, as the conflict continues or worsens, it may further impact our business, financial condition or results of operations during the remainder of fiscal 2023.

As we continue to monitor the ongoing COVID-19 pandemic, our top priority remains protecting the health and safety of our employees, their families and those in our communities. Safety guidelines and procedures are in place for on-site employees and these policies are regularly monitored and updated by our internal Emergency Response Team.

27

COVID-19 continues to impact our business operations and financial results. A number of our product lines have been negatively impacted due to decreased demand in our customers’ businesses around the world. Many of our markets have recovered or are recovering, but the pandemic has continued to adversely impact our customers and ultimately, our revenues. We have also experienced supply chain difficulties directly related to COVID, including vendor disruptions, border closures, shipping issues and significantly increased shipping ~~costs;~~costs, labor shortages and higher labor costs, as we have had to use staffing agencies and increase our base pay in a number of areas of the Company to fill open positions and to cover for COVID-related absences.

24

Overall, the impact of COVID-19 remains uncertain and ultimately depends on the continued duration and severity of the pandemic, inclusive of the introduction of new strains of the virus; government actions taken in response; vaccination rates and effectiveness; the impact of vaccination requirements; extent of protection provided by prior viral infection; and the macroeconomic environment.pandemic. We ~~will~~ continue to evaluate the nature and extent to which COVID-19 has impacted our business, including supply chain, labor availability and attrition, consolidated results of operations, financial condition, and ~~liquidity; we~~liquidity. We expect it to continue to impact us through at least the end of our fiscal year ending May 31, 2023.

Executive Overview


	Three Months ended November 30,									Six Months ended November 30,									Three Months Ended February 28,									Nine Months Ended February 28,
(in thousands)	2022			2021			%			2022			2021			%			2023			2022			%			2023			2022			%
Consolidated
Revenues	$	230,033		$	130,517			76	%	$	362,382		$	258,822			40	%	$	218,255		$	128,244			70	%	$	580,637		$	387,066			50	%
Core Sales Growth								7	%								5	%								4	%								5	%
Food Safety
Revenues	$	161,343		$	67,132			140	%	$	225,986		$	129,854			74	%	$	151,542		$	62,756			141	%	$	377,528		$	192,610			96	%
Core Sales Growth								6	%								6	%								6	%								6	%
Animal Safety
Revenues	$	68,690		$	63,385			8	%	$	136,396		$	128,968			6	%	$	66,713		$	65,488			2	%	$	203,109		$	194,456			4	%
Core Sales Growth								7	%								4	%								2	%								3	%

% of International Sales		50	%		41	%					46	%		40	%					50	%		40	%					47	%		40	%
Effective Tax Rate		n/a			16.2	%					n/a			19.5	%				N/A				18.1	%					4.2	%		19.3	%
Net Income (Loss)	$	(41,841	)	$	10,828			-486	%	$	(36,632	)	$	27,905			-231	%	$	8,190		$	5,443			50	%	$	(28,442	)	$	33,348			(185	)%
Per Diluted Share	$	(0.19	)	$	0.10					$	(0.23	)	$	0.26						0.04			0.05						(0.16	)		0.31
EBITDA*	$	12,639		$	18,533			-32	%	$	24,059		$	45,739			-47	%		42,031			12,651			232	%		66,090			58,390			13	%
Adjusted EBITDA*	$	64,051		$	29,594			116	%	$	91,070		$	58,490			56	%		51,271			24,853			106	%		142,341			83,343			71	%
Adjusted Net Income*	$	31,361		$	20,513			53	%	$	48,917		$	40,623			20	%		26,529			16,237			63	%		75,446			56,860			33	%
Cash (for) from Operations										$	(32,869	)	$	41,057															(49,938	)		47,648

*	~~Refer to non-GAAP financial measures section in this document.~~

•

~~Food Safety core sales exclude revenues from the acquisitions of Delf/Abbott Analytical (November 2021) and~~ * Refer to non-GAAP financial measures section in this document.~~Thai-Neo~~ ~~Biotech (July 2022) and also excludes the change in currency rates.~~

•

Food Safety core year to date sales exclude revenues from the acquisitions of FSD (September 2022), Thai-Neo Biotech (July 2022) and Delf/Abbott Analytical (November 2021) and also excludes the change in currency rates. Food Safety core quarter to date sales exclude revenues from the acquisitions of FSD (September 2022) and Thai-Neo Biotech (July 2022) and also excludes the change in currency rates.

•

Food Safety revenues include ~~$92.7~~$87.0 million and $179.7 million from ~~the~~ 3M FSD, which we combined with on September 1, ~~2022.~~2022, during the three and nine months ended February 28, 2023, respectively. All of the global revenue from this business is reported within the Food Safety segment.

•

Animal Safety core sales year to date exclude revenues from the acquisitions of CAPInnoVet (September 2021) and Genetic Veterinary Sciences (December 2021) and also excludes the change in currency rates.

•

Our net loss was $41.8 million, or ($0.19) per share, in the second quarter of fiscal 2023 compared to net income of $10.8 million, or $0.10 per share, in the second quarter of the prior year, adversely impacted by $39.1 million in legal, consulting and other expenses related to our combination with 3M’s Food Safety business. Year to date, our net loss was $36.6 million compared to income of $27.9 million in the prior year, adversely impacted by $52.9 million in legal, consulting and other expenses. Additionally, ~~non-cash~~ ~~amortization and interest expense, both resulting from the 3M transaction, contributed to the net loss in the quarter and year to date periods.~~

25

International sales ~~rose 114% in~~increased 113% and 77% during the ~~second quarter of fiscal~~three and nine months ended February 28, 2023 ~~and also increased 60% for the year to date, each~~ compared to the same respective periods in the prior year. Revenues from ~~the 3M~~ FSD drove the international sales increase. InDuring the ~~second quarter~~three and nine months ended February 28, 2023, 69% and 67% of ~~fiscal 2023, the~~ FSD revenues, respectively, were ~~comprised of 66%~~ international sales, compared to Neogen’s historical average of 40%.

~~Core~~28

International core growth, which excludes ~~international~~ revenues from FSD, Delf, Genetic Veterinary Sciences and Thai-Neo, and considers a neutral currency impact, was ~~6% for both~~9% and 7% during the ~~second quarter~~three and ~~year to date periods.~~nine months ended February 28, 2023, respectively. The negative impact of currency, primarily from the stronger U.S. dollar against the pound, ~~euro,~~ Chinese yuan and Australian dollar for each comparative period, was $5$2.4 million in the ~~second~~third quarter and ~~$8.9~~$11.2 million year to date. Revenue changes, expressed in percentages, ~~for~~during the three and ~~six month periods of fiscal~~nine months ended February 28, 2023 compared to the same period in the prior year are as follows for the legacy business at each of our international locations:


	Three Months Ended November 30, 2022						Six Months Ended November 30, 2022						Three Months Ended February 28, 2023						Nine Months Ended February 28, 2023
	Revenue % Inc (Dec) USD			Revenue % Inc (Dec) Local Currency			Revenue % Inc (Dec) USD			Revenue % Inc (Dec) Local Currency			Revenue % Inc (Dec) USD			Revenue % Inc (Dec) Local Currency			Revenue % Inc (Dec) USD			Revenue % Inc (Dec) Local Currency
U.K. Operations (including Neogen Italia)		(8	)%		9	%		(2	)%		14	%		(4	)%		7	%		(3	)%		12	%
Megazyme		(7	)%		8	%		(10	)%		4	%		(6	)%		0	%		(9	)%		3	%
Brazil Operations		21	%		16	%		17	%		15	%		12	%		7	%		16	%		13	%
Neogen Latinoamerica		5	%		1	%		11	%		10	%		8	%		0	%		10	%		6	%
Neogen Argentina		21	%		85	%		27	%		82	%		(32	)%		18	%		9	%		61	%
Neogen Uruguay		(11	)%		(17	)%		(6	)%		(13	)%		(15	)%		(24	)%		(9	)%		(16	)%
Neogen Chile		4	%		20	%		0	%		18	%		19	%		20	%		6	%		19	%
Neogen China		(9	)%		1	%		(14	)%		(7	)%		(29	)%		(23	)%		(19	)%		(13	)%
Neogen India		9	%		20	%		17	%		27	%		(25	)%		(17	)%		(1	)%		7	%
Neogen Canada		4	%		12	%		(2	)%		4	%		(2	)%		4	%		(2	)%		4	%
Neogen Australasia		(4	)%		7	%		(6	)%		3	%		12	%		17	%		(1	)%		7	%

In local currency, combined revenues at our U.K. operations increased ~~9% in~~7% and 12% during the ~~second quarter~~three and ~~14% year to date, each~~nine months ended February 28, 2023, respectively, compared to the same periods in the prior year. Excluding the December 2021 acquisition of Delf (UK), sales at our U.K. operations ~~increased 2%~~ in local currency inincreased 7% during the ~~second quarter and 7% for the year to date. Sales~~nine months ended February 28, 2023. In local currency, sales of food quality products at Megazyme, located in Ireland, were flat for the three months ended February 28, 2023 and increased 8%3% during the nine months ended February 28, 2023.

Brazil revenues increased 7% and 13% in local currency ~~driven by increased volume~~during the three and ~~a significant research project.~~

~~Sales in Brazil increased 16% in local currency in this year’s second quarter and 15% year to date,~~nine months ended February 28, 2023, respectively. These increases were driven by strong sales of the company’s ~~mycotoxin~~natural toxin test kits, including tests to detect aflatoxin in corn, ~~and deoxynivalenol (DON) in wheat,~~ as well as increases in veterinary instruments, insect and rodent controls products, and genomics testing.

In local currency, Neogen Latinoamerica ~~sales rose 1% in local currency~~revenues were flat for the ~~second quarter~~three months ended February 28, 2023 and ~~10% year to date, with increases across~~increased 6% for the nine months ended February 28, 2023. Increases in the company’s diagnostic testing portfolio and culture media, ~~partially~~were offset by lower cleaner &and disinfectant sales, ~~in the second quarter,~~ due to order timing from a large distributor. ~~Sales at~~

Neogen China ~~increased 1%~~revenues decreased 23% and 13% in local currency ~~for~~during the three ~~month period but declined 7% for~~and nine months ended February 28, 2023, respectively. The first and second quarters in fiscal 2023 were negatively impacted by COVID-19 lockdowns. As the ~~year to date. A significant order~~Chinese government lifted COVID restrictions early in our third fiscal quarter, business was adversely impacted by staffing shortages throughout the country as a high percentage of ~~cleaners and disinfectants in the second quarter, in advance of Chinese New Year, offset declines in other product lines as the country’s~~ individuals contracted COVID.~~COVID-19~~ ~~related lockdowns continued to negatively impact sales for the respective periods.~~

Revenues at Neogen’s Australasia operations increased 17% and 7% ~~and 3% for~~during the three and ~~six month periods as~~nine months ended February 28, 2023, respectively, led by increased sales of bovine genomic ~~service increases.were partially offset by a large~~ ~~non-recurring~~services. ~~culture media order in the prior year.~~

Service revenue, which includes genomics testing and other laboratory services, was ~~$26.7~~$27.6 million in the ~~second~~third quarter of fiscal 2023, an increase of 9%3% over the prior year ~~second~~third quarter revenues of ~~$24.4~~$26.7 million. ~~Excluding~~

29

During the contribution from the December 2021 acquisition of Genetic Veterinary Sciences and negative currency impact, global genomics service revenue increased 8% in the second quarter. For the six month period,nine months ended February 28, 2023, service revenue was ~~$52.3~~$79.8 million, an increase of 7%6% over prior year revenues of ~~$48.7~~$75.4 million. ~~Strong sales of our Neogen Analytics software as a service (SaaS) product and~~The increase was primarily driven by growth in the beef markets in the U.S. and Brazil for genomics testing ~~was~~our and strong sales of Neogen Analytics software as a service (SaaS) product. These were partially offset by ongoing COVID-related shutdowns in China, lower genomics sales to the porcine market, as a significant customer shifted to a lower-cost competitor, and a difficult comparison due to a large domestic research project recorded in the prior year which did not repeat.

Revenues

26


	Three Months Ended February 28,
(in thousands)	2023		2022		Increase/(Decrease)			%
Food Safety
Natural Toxins, Allergens & Drug Residues	$	19,198	$	17,965	$	1,233			7	%
Bacterial & General Sanitation		39,444		11,288		28,156			249	%
Culture Media & Other		77,955		18,145		59,810			330	%
Rodent Control, Insect Control & Disinfectants		9,550		9,577		(27	)		(0	)%
Genomics Services		5,395		5,781		(386	)		(7	)%
		151,542		62,756		88,786			141	%
Animal Safety
Life Sciences	$	1,440	$	1,339	$	101			8	%
Veterinary Instruments & Disposables		15,428		17,047		(1,619	)		(9	)%
Animal Care & Other		8,735		9,449		(714	)		(8	)%
Rodent Control, Insect Control & Disinfectants		20,242		18,359		1,883			10	%
Genomics Services		20,868		19,294		1,574			8	%
		66,713		65,488		1,225			2	%
Total Revenues	$	218,255	$	128,244	$	90,011			70	%


	Nine Months Ended February 28,
(in thousands)	2023		2022		Increase/(Decrease)			%
Food Safety
Natural Toxins, Allergens & Drug Residues	$	61,236	$	59,397	$	1,839			3	%
Bacterial & General Sanitation		91,293		34,709		56,584			163	%
Culture Media & Other		179,293		56,136		123,157			219	%
Rodent Control, Insect Control & Disinfectants		29,502		25,459		4,043			16	%
Genomics Services		16,204		16,909		(705	)		(4	)%
		377,528		192,610		184,918			96	%
Animal Safety
Life Sciences	$	4,456	$	4,011	$	445			11	%
Veterinary Instruments & Disposables		46,534		47,956		(1,422	)		(3	)%
Animal Care & Other		29,830		29,517		313			1	%
Rodent Control, Insect Control & Disinfectants		63,121		58,777		4,344			7	%
Genomics Services		59,168		54,195		4,973			9	%
		203,109		194,456		8,653			4	%
Total Revenues	$	580,637	$	387,066	$	193,571			50	%

~~Revenues~~

   Three Months Ended
November 30,
(in thousands)    2022    2021    Increase/
(Decrease)    %
Food Safety

Natural Toxins, Allergens & Drug Residues
   $ 22,251    $ 21,028    $ 1,223    6 %
Bacterial & General Sanitation
   41,121    12,252    28,869    236 %
Culture Media & Other
   82,084    19,935    62,149    312 %
Rodent Control, Insect Control & Disinfectants
   10,377    8,232    2,145    26 %
Genomics Services
   5,510    5,685    (175 )    (3 )%







   161,343    67,132    94,211    140 %







Animal Safety

Life Sciences
   $ 1,427    $ 1,309    $ 118    9 %
Veterinary Instruments & Disposables
   16,433    15,572    861    6 %
Animal Care & Other
   10,569    10,849    (280 )    (3 )%
Rodent Control, Insect Control & Disinfectants
   20,665    18,269    2,396    13 %
Genomics Services
   19,596    17,386    2,210    13 %







   68,690    63,385    5,305    8 %







Total Revenues
   $ 230,033    $ 130,517    $ 99,516    76 %

   Six Months Ended
November 30,
(in thousands)    2022    2021    Increase/
(Decrease)    %
Food Safety

Natural Toxins, Allergens & Drug Residues
   $ 42,038    $ 41,432    $ 606    1 %
Bacterial & General Sanitation
   51,849    23,421    28,428    121 %
Culture Media & Other
   101,338    37,981    63,357    167 %
Rodent Control, Insect Control & Disinfectants
   19,952    15,882    4,070    26 %
Genomics Services
   10,809    11,138    (329 )    (3 )%







   225,986    129,854    96,132    74 %







Animal Safety

Life Sciences
   $ 3,016    $ 2,672    $ 344    13 %
Veterinary Instruments & Disposables
   31,106    30,909    197    1 %
Animal Care & Other
   21,095    20,068    1,027    5 %
Rodent Control, Insect Control & Disinfectants
   42,879    40,418    2,461    6 %
Genomics Services
   38,300    34,901    3,399    10 %







   136,396    128,968    7,428    6 %







Total Revenues
   $ 362,382    $ 258,822    $ 103,560    40 %

27

Food Safety

3M’s former Food Safety business (“FSD”), which combined with Neogen on September 1, 2022, consists of five major product lines: indicator organisms (Petrifilm), general sanitation, sample handling, pathogen detection test kits and allergen test kits. All of the global FSD business is ~~currently being~~ reported in Neogen’s Food Safety segment.

Natural Toxins, Allergens & Drug Residues – Sales in this category increased 6%7% and ~~1% for~~3% during the three and ~~six month periods~~nine months ended ~~November 30, 2022,~~February 28, 2023, respectively, compared to the same ~~period~~periods in the prior year. Excluding sales

30

of the acquired allergen product line from 3M, sales in this category decreased 2%3% in both the ~~second~~third quarter and ~~3% for the~~ year to date, primarily due to a significant decline in sales of drug residue test kits to international dairy ~~markets. Natural~~markets as this product line was discontinued. Sales of natural toxin detection kits ~~rose 5% for~~increased 10% during the quarter and ~~were up 4% for the~~increased 6% year to date. The increases for both periods were due to strength in aflatoxin test kits resulting from outbreaks in ~~domestic and~~ international grain ~~harvests, and increases in histamine test kits.~~harvests. Sales of our legacy allergen test kits ~~were flat~~declined in both the ~~second~~third quarter and ~~decreased 5% for the six month period. This decline across the company’s allergen testing portfolio was~~year to date periods, caused by softening market conditions and supply disruptions for certain manufactured products.

Bacterial & General Sanitation – Revenues in this category increased ~~236%~~249% and ~~121% for~~163% during the ~~second quarter~~three and ~~for the year to date, each~~nine months ended February 28, 2023, respectively, compared to the same periods in the prior year. Excluding the contribution of the ~~Biotrace~~Cleantrace line of general sanitation products and the pathogen test kit product line, both acquired from 3M, organic sales in this category ~~were flat~~increased 1% in the ~~second~~third quarter and ~~declined 2% for the six months, each compared to the same period~~decreased 1% in the ~~prior year.~~year to date periods. In the ~~second~~third quarter, ana strong increase in sales of ~~filters and ampoule media to beverage manufacturers and~~our Soleris line of spoilage detection products was partially offset by a ~~5% increase~~decrease in sales of our AccuPoint line of general sanitation products, ~~were offset~~primarily caused by ~~lower sales of Soleris~~^® ~~equipment and consumables as worsening global economic conditions caused customers to delay capital purchases and reduce sampling volumes.~~supply disruptions.

Culture Media & Other – Sales in this category increased ~~312% in~~330% and 219% during the ~~quarter~~three and nine months ended ~~November 30, 2022~~February 28, 2023, respectively, compared to the ~~second quarter~~same periods in the prior ~~year; for the six month period, sales increased 167%.~~year. Excluding sales of the Petrifilm indicator organism and ~~sampling~~sample handling product lines acquired from 3M, sales ~~were flat~~rose 14% in the ~~second~~third quarter and increased ~~3% for the~~7% year to date. ~~Within this category,~~The increase in the third quarter was primarily due to a large sale of custom culture media. Additionally, sales of our Neogen Analytics software as a service platform increased significantly, with approximately ~~175~~200 sites now on contract. ~~Additionally, an 11% increase in~~Decreased sales of ~~culture media products in the second quarter, primarily due to a large sale to a vaccine manufacturer, was offset by a decline in~~ food quality test kits ~~which was~~that were negatively impacted by ~~currency.~~lower volumes and currency partially offset the growth in this category.

Rodent Control, Insect Control & Disinfectants – Revenues in this category ~~increased 26%~~were flat for ~~both~~ the three months ended February 28, 2023 and ~~six month periods; excluding~~increased 16% during the ~~revenue contribution from~~nine months ended February 28, 2023 compared to the ~~Delf acquisition in this category, the overall increase was 11%~~same periods in the ~~second quarter and 10%~~prior year. The increase for the year to ~~date. The increase in the second quarter~~date was due to a large insect control order to a government agency in Brazil and ~~a significant order of cleaners~~ongoing strength in cleaner and ~~disinfectants to China~~disinfectant revenues in ~~advance of Chinese New Year.~~China.

Genomics Services – Sales of genomics services sold through our international Food Safety operations decreased ~~3% for both~~7% and 4% during the three and ~~six month~~nine months ended February 28, 2023, respectively, compared to the same periods ~~ended November 30, 2022.~~in the prior year. For each comparative period, unfavorable currency comparisons in the U.K. and COVID-related lab closures in China offset increased beef genomics testing business in Brazil.

Animal Safety

Life Sciences – Sales in this category increased ~~9% in~~8% and 11% during the ~~second quarter~~three and nine months ended February 28, 2023, respectively, compared to the same ~~period~~periods in the prior ~~year; for the year to date, the increase in this product line was 13%.~~year. The increase for both comparative periods was due to higher demand from customers purchasing substrates and reagents used in clinical diagnostic test kits, and increased demand from forensic toxicology lab customers due to their higher testing volumes.

Veterinary Instruments & Disposables – Revenues in this category ~~increased 6%~~decreased 9% and ~~1% for~~3% during the three and ~~six month~~nine months ended February 28, 2023, respectively, compared to the same periods ~~ended November 30, 2022, respectively. For~~in the ~~second~~prior year. In the third quarter ~~disposable product~~of the prior fiscal year, sales ~~increased significantly, as~~in this category rose 38% due to new ~~products were added by~~business earned with a large retail customer. ~~Additionally, sales of veterinary instruments increased 4% off a strong prior year comparison; sales of these products were 35% higher than sales in the second quarter of fiscal 2021. For the year~~Year to date, ~~period,~~ veterinary instrument sales were ~~up 1%, again~~down slightly, due to a difficult prior year comparison.

Animal Care & Other – Sales of these products decreased 3%8% during the three months ended February 28, 2023 and increased 1% during the nine months ended February 28, 2023 compared to the same periods in the ~~second quarter; year to date sales increased 5%. Excluding the contribution of parasiticides from the September 2021 acquisition of CAPInnoVet, revenues increased 2% for the six month period.~~prior year. Within this category, sales of animal care products ~~were flat~~declined 8% in the ~~second~~third quarter, as lower sales of antibiotics and vitamin injectables were only partially offset by increases in ~~parasiticides and our Botulism B vaccine for horses were offset by declines in vitamin injectables~~small animal supplements and wound care products.

28

31

Rodent Control, Insect Control & Disinfectants – Revenues increased ~~13%~~10% and 6%7% for the three and ~~six month periods~~nine months ended ~~November 30, 2022, each~~February 28, 2023, respectively, compared to the same ~~period~~periods in the prior year. In the ~~second~~third quarter, sales of ~~cleaners and disinfectants~~insecticides increased ~~26%~~37%, with new business earned in the animal protein ~~market and strong sales of dairy hygiene products. Insect control products rose 13% in the quarter and rodenticide~~market. Rodenticide sales increased 6%4% and cleaner and disinfectant sales declined 3%. ~~For the year~~Year to date, increases in cleaners and disinfectants and insect control product lines were partially offset by a 2% decline in sales of rodent control products in the first ~~quarter~~half of fiscal 2023.

Genomics Services – Sales in this category increased ~~13%~~8% and ~~10% in~~9% during the ~~second quarter~~three and ~~the year to date periods, each~~nine months ended February 28, 2023, respectively, compared to the ~~prior year; excluding the contribution from Genetic Veterinary Sciences, revenues increased 4%~~same periods in the ~~second quarter and 1% for the year to date.~~prior year. For both comparative periods, ~~domestic~~testing increases in the beef market were partially offset by ~~unfavorable currency comparisons in Australia,~~ lower sample volumes from a large customer in the porcine market and ~~a difficult prior year comparison due to a large research project which did not recur.~~unfavorable currency comparisons in Australia.

Gross Margin

Gross margin, expressed as a percentage of sales, was ~~48.9%~~49.5% in the ~~second~~third quarter of fiscal 2023 compared to ~~46.4%~~44.8% in the ~~same quarter a~~prior year ~~ago.~~comparable period. The increase was primarily due to the incremental revenues from the FSD merger, which generated gross margin higher than the legacy company average margin. The legacy Neogen Food Safety business recorded a gross margin improvement of ~~280~~20 basis points compared to the same quarter a year ago, while Animal Safety gross margins increased ~~140~~220 basis ~~points, each due~~points. These increases were driven primarily toby pricing actions ~~taken~~executed within the past 12 months. Within each segment, increased raw material costs continued to pressure gross margins in certain product ~~lines; however,~~lines. However, freight in costs ~~dropped~~declined significantly during the comparative period particularly benefitting the Animal Safety segment, although they remained higher in some areas than pre-pandemic levels. ~~For the year~~Year to date, gross margin was ~~48.2%~~48.7% compared to ~~46.6%~~46.0% in the prior year, driven primarily ~~the result of the~~by higher gross margins from the acquired FSD product lines, and pricing actions ~~taken~~executed in the prior 12 to 18 months in the legacy Neogen Food and Animal Safety product lines.

Operating Expenses

Operating expenses were ~~$120.2~~$92.3 million in the ~~second~~third quarter of fiscal 2023, compared to ~~$48.1~~$51.0 million in the same quarter of the prior year. ~~Legal, consulting and other professional fees and expenses totaling $39.1 million were incurred in~~During the second quarter of the current fiscal year related to our combination with the 3M FSD, which closed on September 1, 2022. In the prior fiscal year second quarter, $9.3 million in deal costs relating to this transaction were incurred. In addition to the deal costs incurred in the current quarter, the Company recorded $20.3 million in amortization expenses relating to the intangible assets acquired in the merger, and $16.8 million in compensation and related expenses for the conveyed employees. Excluding costs related to the transaction and the absorbed business, run ratenine months ended February 28, 2023, operating expenses ~~for the legacy business for the second quarter~~ were ~~$44.4 million, an increase of $5.6~~$268.7 million, compared to ~~$38.8~~$137.4 million in the same period in the prior year. ~~Operating~~For each comparative period, the increase was primarily the result of legal, consulting and other expenses ~~for businesses acquired in the past year, excluding~~related to the FSD ~~business, totaled $1.5 million~~transaction and ~~represented 27% of~~ongoing expenses resulting from the ~~increase in operating expenses for~~conveying employees and the ~~second quarter of fiscal 2023.~~

~~For the six month period ended November 30, 2022, operating expenses of $176.4 million included $52.9 million in deal costs relating to the combination with the 3M FSD, $20.3 million in~~ amortization of intangible assets acquired in the FSD merger, and $16.3 million in compensation and related operating expenses for the conveyed FSD employees. Run rate operating expenses for the legacy operating business were $86.9 million, an increase of $9.8 million, or 13% over the same period in the prior year, after adjusting for $9.3 million in deal costs incurred. Operating expenses for businesses acquired in the past year, excluding the FSD business, totaled $3.6 million and represented 37% of the increase in operating expenses for the first half of fiscal 2023.transaction.

Sales and marketing expenses were ~~$36.3~~$38.6 million in the ~~second~~third quarter of fiscal 2023, compared to ~~$21.2~~$21.5 million in ~~last year’s second quarter.~~the same quarter of the prior year. The increase in expense was due primarily to ~~$12.9~~$14.8 million in costs incurred for the FSD business, primarily consisting of compensation and related expenses for ~~the~~ conveying FSD sales and marketing team, ~~effective September 1, 2022. Included in those expenses were amounts~~and the charges for transition services provided by ~~3M for~~3M. These invoicing and ~~distribution. These costs~~distribution services will be provided under contract for a period of up to 18 ~~months.~~months, concluding on March 1, 2024. The remainder of the increase ~~for~~during the quarter was due primarily to higher personnel related spending in the legacy business, the result of headcount additions and compensation increases. In addition, travel, trade shows and other customer facing activities have continued to increase with the easing of COVID-19 ~~restrictions. For the year~~ restrictions and greater willingness by customers to interact. Year to date, sales and marketing expenses were ~~$59.7~~$98.3 million, ~~an increase of $18.0~~compared to $63.2 million ~~over~~in the same period ~~last year;~~in the prior year. The increase was driven by ~~$12.9~~$27.7 million in absorbed expenses from personnel conveying in the FSD transaction, higher personnel related expenses in the legacy business, and increased travel, trade shows and other customer facing activities. ~~Sales and marketing expenses from other acquired businesses were $600,000 and $1.5 million for the three and six month periods, respectively.~~

29

32

General and administrative expenses were ~~$77.0~~$46.4 million in the ~~second~~third quarter of fiscal 2023, ~~and included $39.1~~compared to $25.0 million in ~~legal, consulting~~the same quarter of the prior year. The current quarter included $2.3 million of goodwill and ~~other professional fees and expenses~~intangible asset impairment related to certain discontinued product lines and $20.3 million in amortization for intangible assets acquired in our combination with the 3M FSD, which closed on September 1, 2022. ~~After adjusting~~Remaining increases for ~~these deal-related expenses, and an additional $1.4 million in incremental expenses incurred in absorbing~~ the ~~business into Neogen, second~~ quarter ~~run rate general and administrative expenses~~ were ~~$16.2 million, an increase of $2.9 million, or 22%, compared to the same period a year ago. The increase was~~ primarily the result of additional personnel hired to accommodate the increased size and complexity of the organization, compensation increases across the organization, ~~including at the senior leadership level,~~ the issuance of share based compensation grants, software license fees and other information technology infrastructure ~~investments~~investments. These increases were partially offset by a $9.6 million decrease in legal, professional, and ~~$800,000 in incremental operating expenses from our other recent acquisitions, including amortization of intangible assets acquired. For the year~~consulting fees. Year to date, ~~after adjusting for the $52.9~~general and administrative expenses were $151.4 million in ~~deal costs~~fiscal 2023, compared to $61.0 million in the comparable prior period. Fiscal year 2023 included $55.8 million in transaction fees and integration expenses resulting from the combination with the 3M FSD and ~~$20.3~~other acquisitions and $40.6 million in amortization of intangibles acquired in the FSD ~~merger, run rate general and administrative expenses~~merger. For the comparative period in fiscal year 2022, transaction costs were $31.7 million, an increase of $5.0 million compared to the same period a year ago. General and administrative expenses from recent acquisitions, excluding the 3M FSD combination, were $1.3 million of the increase.$19.9 million.

Research and development expense was ~~$6.8~~$7.3 million in the ~~second~~third quarter of fiscal 2023, ~~an increase of $2.5 million, or 58%,~~ compared to $4.6 million in the same ~~period in~~quarter of the prior year. The increase was primarily the result of ~~$2.0~~$3.2 million of cost associated with the conveying FSD ~~employees,~~employees. Year to date, research and ~~outside~~development expenses were $19.0 million, compared to $13.2 million in the same period in the prior year. The year to date increase is primarily driven by $5.2 million of expense for conveying FSD personnel and testing and validation costs for new commercial products ~~under development~~ in the Animal Safety segment. ~~For the year to date, research and development expenses were $11.7 million compared to $8.7~~

Operating Income

Operating income was $15.7 million in the ~~same period last year, with the increase due primarily to the $2.0 million in conveying FSD personnel and testing and validation for new commercial products in the Animal Safety segment.~~

~~Operating Income (Loss)~~

~~The operating loss was $7.7 million in the second~~third quarter of fiscal 2023, compared to operating income of ~~$12.5~~$6.4 million in the ~~same period of the~~ prior ~~year. For the~~ year comparable period. Year to date, ~~period, the~~ operating ~~loss~~income was ~~$1.6~~$14.1 million compared to operating income of ~~$34.2~~$40.6 million in the prior year. Expressed as a percentage of sales, operating income was 7.2% during the ~~operating loss was 3.3% for the second~~third quarter and ~~0.4% for the~~2.4% year to date, compared to operating income of ~~9.6%~~5.0% and ~~13.2%~~10.5%, respectively, for the same periods in the prior year. ~~Adjusting for~~Year to date operating income, both in dollars and expressed as a percentage of sales, declined compared to the ~~$39.1 million in~~prior year comparative period primarily due to transaction costs resulting from the 3M transaction in the second quarter, and $52.9 million of these costs for the year to date period, operating income was $31.4 million, or 13.7% in the second quarter and $51.3 million, or 14.2% for the year to date. After adjusting out $9.3 million in deal costs incurred in both the second quarter and year to date periods in fiscal 2022, prior year operating income for those periods was $21.8 million, or 16.7%, and $43.5 million, or 16.8%. The primary reason for the lower operating income percentage in each comparative period was theFSD merger, amortization of the intangible assets acquired, ~~in conjunction with the FSD merger.~~and impairment costs related to discontinued product lines.

Other (Expense)/Income


	Three Months Ended						Six Months Ended
	November 30,						November 30,						Three Months Ended February 28,						Nine Months Ended February 28,
(dollars in thousands)	2022			2021			2022			2021			2023			2022			2023			2022
Interest income	$	553		$	246		$	1,523		$	455		$	640		$	349		$	2,163		$	804
Interest expense		(20,545	)		(22	)		(20,547	)		(28	)		(17,460	)		(35	)		(38,007	)		(63	)
Foreign currency transactions		(6,108	)		167			(6,530	)		15			243			(185	)		(6,287	)		(170	)
LGS contingent consideration		—			(135	)		—			(135	)
Loss on sale of minority interest														(1,516	)		-			(1,516	)		-
Contingent consideration adjustments														300			-			300			(135	)
Other		(335	)		203			(284	)		134			(151	)		137			(435	)		271

Total Other Income	$	(26,435	)	$	459		$	(25,838	)	$	441

Total Other (Expense) Income													$	(17,944	)	$	266		$	(43,782	)	$	707

The net interest expense ~~incurred for~~recorded during the three and ~~six month periods~~nine months ended ~~November 30, 2022~~February 28, 2023 was the result of ~~the $1 billion in~~ debt incurred to fund the 3M FSD ~~combination.~~transaction. In fiscal 2022, the Company had no debt outstanding, and interest income relates to earnings on our marketable securities portfolio. Higher yields on the portfolio were partially offset by lower balances. Other ~~income or~~ expense resulting from foreign currency transactions was the result of changes in the value of foreign currencies relative to the U.S. dollar in countries in which we ~~operate; the~~operate. The increase in expense ~~for~~during the ~~second quarter and year to date periods in fiscal~~nine months ended February 28, 2023 was due to U.S. dollar denominated intercompany loans incurred in our international subsidiaries as the result of the FSD transaction on September 1, 2022. Due to our acquisition of Corvium, Inc., we recorded a loss of $1.5 million in the third quarter on dissolution of our minority interest in that company.

33

Provision for Income Taxes

30

~~Income Tax Expense~~

Income tax ~~expense~~benefit in the ~~second~~third quarter of fiscal 2023 was ~~$7.8~~$10.5 million, compared to ~~$2.1~~$1.2 million of income tax expense in the ~~same period of the~~ prior ~~year; for the~~ year comparable period. Year to date, income tax ~~expense~~benefit was ~~$9.2~~$1.3 million, compared to ~~$6.8~~$8.0 million of income tax expense in fiscal 2022. Income tax ~~expense~~benefit in the ~~second~~third quarter of fiscal 2023 includes approximately ~~$6.7~~$1.1 million of expense related to non-deductible transaction costs associated with the 3M FSD ~~transaction and $625,000 of expense due to an increase in our deferred tax liability rate. In each comparative period, there was minimal benefit from the exercise of stock options.~~transaction.

The total amounts of unrecognized tax benefits that, if recognized, would affect the effective tax rate as of ~~November 30, 2022~~February 28, 2023 and May 31, 2022 are ~~$1.4~~$1.5 million and $808,000, respectively. The increase in unrecognized tax benefits is primarily associated with the combined 3M FSD, including positions for transfer pricing and research and development credits.

Net Income (Loss)

~~The Company incurred a net loss of $41.8~~Net income was $8.2 million in the ~~second~~third quarter of fiscal 2023, compared to net income of ~~$10.8~~$5.4 million in the same period in the prior year. The ~~decline~~increase in earnings ~~for~~during the quarter was primarily the result of ~~$39.1 million in legal, consulting, professional fees and other expenses~~incremental revenues from the 3M FSD ~~transaction, $20.0~~merger, which generated margins higher than the legacy company average margin. This increase was partially offset by $1.3 million of goodwill impairment related to discontinued product lines, $17.5 million of interest expense from the $1 billion in debt incurred in the merger, and $20.3 million in incremental amortization expenses associated with the intangible assets acquired in the merger. ~~For~~During the ~~year to date,~~nine months ended February 28, 2023, the Company incurred a net loss of ~~$36.6~~$28.4 million, compared to net ~~earnings~~income of ~~$27.9~~$33.3 million in the prior year. ~~Three~~The decline in earnings during the year was primarily the result of $1.3 million of goodwill impairment related to discontinued product lines, $38.0 million of interest expense from the $1 billion in debt incurred in the merger, $55.8 million of transaction fees and ~~six month net income~~integration expenses, and $40.6 million in ~~fiscal 2023 was also negatively impacted by a higher effective tax rate.~~incremental amortization expenses.

Non-GAAP Financial Measures

This report includes certain financial information for the Company that differs from what is reported in accordance with GAAP. These non-GAAP financial measures consist of core revenue growth, EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Net Income and Adjusted Earnings per Share. These non-GAAP financial measures are included in this report because management believes that they provide investors with additional useful information to measure the performance of the Company, and because these non-GAAP financial measures are frequently used by securities analysts, investors and other interested parties as common performance measures to compare results or estimate valuations across companies in industries the Company operates in.

Core revenue growth

We define core revenue growth as net sales for the period excluding the impacts of foreign currency translation rates and the first year impacts of acquisitions and ~~disposals,~~divestitures, where applicable. We present core revenue growth because it allows for a meaningful comparison of results across periods without the volatility caused by foreign currency gains or losses, or the incomparability that would be caused by the impact of an acquisition or ~~disposal.~~divestiture.

EBITDA

We define EBITDA as net income before interest, income taxes, and depreciation and amortization. We present EBITDA as a performance measure because it may allow for a comparison of results across periods and results across companies in the industries in which Neogen operates on a consistent basis, by removing the effects on operating performance of (a) capital structure (such as the varying levels of interest expense and interest income), (b) asset base and capital investment cycle (such as depreciation and amortization) and (c) items largely outside the control of management (such as income taxes). EBITDA also forms the basis for the measurement of Adjusted EBITDA (discussed below).

34

Adjusted EBITDA

We define Adjusted EBITDA as EBITDA, adjusted for share-based compensation and certain transaction fees and expenses. We present Adjusted EBITDA because it provides an understanding of underlying business performance by excluding the following:

•

Share-based compensation. We believe it is useful to exclude share-based compensation to better understand the long-term performance of our core business and to facilitate comparison with the results of peer companies.~~. We believe it is useful to exclude share-based compensation to better understand the long-term performance of our core business and to facilitate comparison with the results of peer companies.~~

•

~~Other income/(expense). We exclude items in other income/(expense), which consists of primarily foreign currency transactions and, to a lesser extent,~~ ~~one-time~~ ~~amounts unrelated to our core business, to better understand the long-term performance of our core business.~~

•

~~Certain transaction fees and expenses.~~ We exclude fees and expenses related to certain transactions because they are outside of Neogen’s underlying core performance. These fees and expenses include deal related professional and legal fees and foreign currency transactions.

•

~~Other~~ ~~one-time~~ ~~adjustments.~~ ~~We exclude~~ ~~one-time~~ ~~adjustments recorded within operating income to better understand the long-term performance of our core business.~~

31

•

FX translation gain/(loss) on loan revaluation. We exclude the revaluation impacts of foreign currency fluctuations on our intercompany loan balances.

•

Certain transaction fees and expenses. We exclude fees and expenses related to certain transactions because they are outside of Neogen’s underlying core performance. These fees and expenses include deal related professional and legal fees and foreign currency transactions.

•

Impairment and scrap of discontinued product lines. We exclude expenses associated with impairments and inventory scrap amounts related to certain discontinued product lines.

•

Other one-time adjustments. We exclude one-time adjustments recorded within operating income to better understand the long-term performance of our core business.

Adjusted EBITDA margin

We define Adjusted EBITDA margin as Adjusted EBITDA as a percentage of total revenues. We present Adjusted EBITDA margin as a performance measure to analyze the level of Adjusted EBITDA generated from total revenue.

Adjusted Net Income

We define Adjusted Net Income as Net Income, adjusted for share-based compensation, ~~other income/(expense),~~FX translation gain/(loss) on loan revaluation, certain transaction fees and expenses, and other one-time adjustments, all of which are tax effected.

Adjusted Earnings per Share

We define Adjusted Earnings per Share as Adjusted Net Income divided by diluted average shares outstanding.

These non-GAAP financial measures are presented for informational purposes only. EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Net Income and Adjusted Earnings per Share are not recognized terms under GAAP and should not be considered in isolation or as a substitute for, or superior to, net income (loss), operating income, cash flow from operating activities or other measures of financial performance. This information does not purport to represent the results Neogen would have achieved had any of the transactions for which an adjustment is made occurred at the beginning of the periods presented or as of the dates indicated. This information is inherently subject to risks and uncertainties. It may not give an accurate or complete picture of Neogen’s financial condition or results of operations for the periods presented and should not be relied upon when making an investment decision.

The use of the terms EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Net Income and Adjusted Earnings per Share may not be comparable to similarly titled measures used by other companies or persons due to potential differences in the method of calculation.

These non-GAAP financial measures have limitations as analytical tools. For example, for EBITDA-based metrics:

•

they do not reflect changes in, or cash requirements for, Neogen’s working capital needs;

•

they do not reflect Neogen’s tax expense or the cash requirements to pay taxes;

•

they do not reflect the historical cash expenditures or future requirements for capital expenditures or contractual commitments;

35

•

they do not reflect any cash requirements for future replacements of assets that are being depreciated and amortized; and

•

they may be calculated differently from other companies in Neogen’s industries limiting their usefulness as comparative measures.

~~You~~A reader should compensate for these limitations by relying primarily on the financial statements of Neogen and using these non-GAAP financial measures only as a supplement to evaluate Neogen’s performance.

For each of these non-GAAP financial measures below, we are providing a reconciliation of the differences between the non-GAAP measure and the most directly comparable GAAP measure.

32

Reconciliation between net income and EBITDA and Adjusted EBITDA and between net income margin % and Adjusted EBITDA margin % are as follows:


	Three Months Ended November 30						Six Months Ended November 30						Three Months Ended February 28,						Nine Months Ended February 28,
(dollars in thousands)	2022			2021			2022			2021			2023			2022			2023			2022
Net Income (Loss)	$	(41,841	)	$	10,828		$	(36,632	)	$	27,905		$	8,190		$	5,443		$	(28,442	)	$	33,348
Net income margin %		-18.2	%		8.3	%		-10.1	%		10.8	%		3.8	%		4.2	%		-4.9	%		8.6	%
Provision for income taxes		7,750			2,100			9,200			6,750			(10,450	)		1,200			(1,250	)		7,950
Depreciation and amortization		26,738			5,829			32,467			11,511			27,471			6,322			59,938			17,833
Interest income, net		19,992			(224	)		19,024			(427	)

Interest expense (income), net														16,820			(314	)		35,844			(741	)
EBITDA	$	12,639		$	18,533		$	24,059		$	45,739		$	42,031		$	12,651		$	66,090		$	58,390
Share-based compensation		2,632			1,748			4,499			3,438			2,812			1,607			7,311			5,045
FX transaction loss on loan revaluation⁽¹⁾		5,789			—			5,789			—
Certain transaction fees and expenses		39,132			9,313			52,864			9,313
FX transaction loss (gain) on loan revaluation(1)														(697	)		—			5,092			—
Certain transaction fees and integration costs														2,890			10,595			55,754			19,908
Contingent consideration adjustments														(300	)		—			(300	)		—
Loss on sale of minority interest														1,516			—			1,516			—
Impairment and scrap of discontinued product lines(2)														3,633			—			3,633			—
Inventory step-up charge		3,859			—			3,859			—			(614	)		—			3,245			—

Adjusted EBITDA	$	64,051		$	29,594		$	91,070		$	58,490		$	51,271		$	24,853		$	142,341		$	83,343

Adjusted EBITDA margin %		27.8	%		22.7	%		25.1	%		22.6	%		23.5	%		19.4	%		24.5	%		21.5	%

⁽¹⁾

~~Net foreign currency transaction loss associated with the revaluation of non-functional currency intercompany loans established in connection with 3M Food Safety transaction.~~

(1)

Net foreign currency transaction (gain) loss associated with the revaluation of non-functional currency intercompany loans established in connection with 3M Food Safety transaction.

(2)

Expenses associated with goodwill and intangible asset impairments and inventory scrap amounts related to certain discontinued product lines.

Adjusted EBITDA increased ~~$35.3~~$26.4 million and ~~$33.6~~$59.0 million ~~for~~during the three and ~~six month periods,~~nine months ended February 28, 2023, respectively, due primarily to earnings generated from the 3M FSD business, which merged with Neogen on September 1, 2022. Expressed as a percentage of revenue, adjusted EBITDA was ~~28.1% for~~23.5% during the ~~second~~third quarter of fiscal 2023 compared to ~~23.1% for~~19.4% during the same period last year, and was ~~25.4% for~~24.5% during the ~~six month period.~~nine months ended February 28, 2023 compared to 21.5% during the same period last year. The 3M FSD business was not part of the Company induring the ~~prior six month period; thus,~~nine months ended February 28, 2022. Thus, the adjusted EBITDA amount for that period is not directly comparable.

33

36

Reconciliation between net income and Adjusted Net Income and earnings per share and Adjusted Earnings per Share are as follows:



	Three months ended November 30						Six Months Ended November 30						Three Months Ended February 28,						Nine Months Ended February 28,
(in thousands, except for percentages)	2022			2021			2022			2021			2023			2022			2023			2022
Net Income (Loss)	$	(41,841	)	$	10,828		$	(36,632	)	$	27,905		$	8,190		$	5,443		$	(28,442	)	$	33,348
Earnings per share	$	(0.19	)	$	0.10		$	(0.23	)	$	0.26
Earnings per diluted share													$	0.04		$	0.05		$	(0.16	)	$	0.31
Amortization of acquisition-related intangibles		22,116			1,770			23,957			3,455			22,680			1,977			46,637			5,432
Share-based compensation		2,632			1,748			4,499			3,438			2,812			1,607			7,311			5,045
FX transaction loss on loan revaluation⁽¹⁾		5,789			—			5,789			—
Certain transaction fees and expenses		39,132			9,313			52,864			9,313
FX transaction loss (gain) on loan revaluation(1)														(697	)		—			5,092			—
Certain transaction fees and integration costs														2,890			10,595			55,754			19,908
Contingent consideration adjustments														(300	)		—			(300	)		—
Loss on sale of minority interest														1,516			—			1,516			—
Impairment and scrap of discontinued product lines(2)														3,633			—			3,633			—
Inventory step-up charge		3,859			—			3,859			—			(614	)		—			3,245			—
Other adjustments⁽²⁾		4,350			—			4,350			—
Estimated tax effect of above adjustments⁽³⁾		(4,676	)		(3,146	)		(9,769	)		(3,488	)

Other adjustments(3)														1,514			—			5,864			—
Estimated tax effect of above adjustments(4)														(15,095	)		(3,385	)		(24,864	)		(6,873	)
Adjusted Net Income	$	31,361		$	20,513		$	48,917		$	40,623		$	26,529		$	16,237		$	75,446		$	56,860

Adjusted Earnings per Share	$	0.15		$	0.19		$	0.30		$	0.38		$	0.12		$	0.15		$	0.42		$	0.53

⁽¹⁾

~~Net foreign currency transaction loss associated with the revaluation of non-functional currency intercompany loans established in connection with the 3M FSD transaction.~~

⁽²⁾

~~Income tax expense associated with non-deductible transaction costs that were recognized as expense in prior periods.~~

⁽³⁾

~~Tax effect of adjustments is calculated using projected effective tax rates for each applicable item.~~

(1)

Net foreign currency transaction (gain) loss associated with the revaluation of non-functional currency intercompany loans established in connection with the 3M FSD transaction.

(2)

Expenses associated with goodwill and intangible asset impairments and inventory scrap amounts related to certain discontinued product lines.

(3)

Income tax benefit associated with non-deductible transaction costs that were recognized as expense in prior periods.

(4)

Tax effect of adjustments is calculated using projected effective tax rates for each applicable item.

Adjusted Net Income increased ~~$10.8~~$10.3 million and ~~$8.3~~$18.6 million ~~for~~during the three and ~~six month periods,~~nine months ended February 28, 2023, respectively, due to the higher Adjusted ~~EBITDA partially offset by interest expense.~~EBITDA.

Financial Condition and Liquidity

The overall cash, cash equivalents and marketable securities position of Neogen was ~~$276.3~~$183.2 million ~~at November 30, 2022,~~as of February 28, 2023, compared to $381.1 million atas of May 31, 2022. Cash flow ~~from~~for operating activities was ~~negative $32.9~~$49.9 million during the ~~first six~~nine months ~~of fiscal~~ended February 28, 2023, which was primarily the result of 3M FSD deal-related expenses and ~~inventory increases. Net cash~~recording FSD accounts receivable. Cash flow from investing activities was $194.2 million during the nine months ended February 28, 2023, which was primarily the result of proceeds ~~of $920,000 were realized~~ from the ~~exercise~~sale of ~~stock options~~marketable securities of $233.0 million. This was partially offset by purchases of property, equipment and ~~issuance~~non-current intangible assets of ~~shares under our Employee Stock Purchase Plan~~$40.3 million. Cash flow for financing activities was $118.3 million during the ~~first six~~nine months ~~of fiscal~~ended February 28, 2023. The Company paid down ~~$60~~an additional $40 million in principal on the term loan during the ~~second quarter. We spent $25.1~~third quarter, resulting in a total repayment of $100 million ~~for property, equipment and other~~ ~~non-current~~ ~~assets in the first six months of the~~throughout fiscal year with spending of $3.4 million on our ERP implementation of SAP, $2.4 million on construction of our Lansing manufacturing facility, and approximately $400,000 in IT for laptops and software for the conveying employees related to the FSD business.2023.

Net accounts receivable balances were ~~$142.7~~$146.4 million ~~at November 30, 2022~~as of February 28, 2023 compared to $99.7 million atas of May 31, 2022. Days’ sales outstanding, a measurement of the time it takes to collect receivables, ~~were 54~~was 62 days for the legacy Neogen business ~~at November 30, 2022,~~as of February 28, 2023, compared to 62 days atas of May 31, 2022 and 6364 days ~~at November 30, 2021.~~ as of February 28, 2022. The increase in receivables is primarily attributable to the recording of FSD customer balances, currently managed by 3M as a transition service.

As part of transition services agreements between the Company and 3M, related to the merger of the Food Safety business, 3M is invoicing our customers for products that 3M is manufacturing and shipping on our behalf. ~~At November 30, 2022,~~As of February 28, 2023, there ~~are $46.3~~were $52.2 million in customer receivables billed by 3M on our behalf. The Company is working collaboratively with 3M on managing the credit risk associated with the former FSD customers during the period when 3M is providing transition invoicing and distribution services to the Company. ~~To date, we have not experienced an appreciable increase in bad debt write offs related to the ongoing~~ ~~COVID-19~~ ~~pandemic.~~

37

Net inventory was ~~$136.1~~$143.9 million ~~at November 30, 2022,~~as of February 28, 2023, an increase of ~~$13.8~~$21.6 million, compared to a May 31, 2022 balance of $122.3 million. The higher inventory levels are primarily the result of ~~continued~~raw material inventories purchased to support the FSD and ongoing inflationary pressures on raw materials at our legacy ~~businesses and raw material inventories purchased to support the combined 3M FSD.~~businesses. Supply chain issues have moderated ~~somewhat during the second quarter of~~throughout fiscal ~~2023; we~~2023. We continue to monitor our key raw materials to ensure adequate stock on hand.

Debt and Liquidity

On September 1, 2022, Neogen, 3M, and Garden SpinCo, a newly formed subsidiary of 3M created to carve out 3M’s Food Safety business, closed on the transaction which had previously been announced in December 2021, combining 3M’s Food Safety business with Neogen in a Reverse Morris Trust transaction.

34

On June 30, 2022, Garden SpinCo entered into a credit agreement consisting of a five-year senior secured term loan facility in the amount of $650 million and a five-year senior secured revolving facility in the amount of $150 million (collectively, the “Credit Facilities”), which became available in connection with the merger and related transactions. The loan facility was funded to Garden SpinCo on August 31, 2022, and upon the effectiveness of the merger on September 1, 2022, became Neogen’s obligation. Financial covenants include maintaining specified levels of funded debt to EBITDA and debt service coverage. Pricing for the term loan is term SOFR plus 235 basis points. The Credit Facilities, together with the Notes below, represent the financing incurred in connection with the merger of the 3M FSD with Neogen. OnIn September ~~30,~~ 2022, ~~the Company~~we paid down $60 million in principal on the term ~~loan.~~loan and paid an additional $40 million in principal on the term loan in December 2022, in order to decrease the outstanding debt balance.

InOn July 20, 2022, Garden SpinCo closed on an offering of $350 million aggregate principal amount of 8.625% senior notes due 2030 (the “Notes”) in a private placement at par. The Notes were initially issued by Garden SpinCo to 3M and were transferred and delivered by 3M to the selling securityholder in the offering, in satisfaction of certain of 3M’s existing debt. Garden SpinCo did not receive any proceeds from the sale of the Notes by the selling securityholder. Prior to the distribution of the shares of Garden SpinCo’s common stock to 3M stockholders, the Notes were guaranteed on a senior unsecured basis by 3M. Upon consummation of such distribution, 3M was released from all obligations under its guarantee. Upon the effectiveness of the merger on September 1, 2022, the Notes became guaranteed on a senior unsecured basis by Neogen and certain wholly-owned domestic subsidiaries of Neogen.

In addition to the 3M transaction described above, our future cash generation and borrowing capacity may not be sufficient to meet cash requirements to fund the operating business, repay debt obligations, construct new manufacturing facilities, commercialize products currently under development or execute our future plans to acquire additional businesses, technology and products that fit within our strategic plan. Accordingly, we may be required, or may choose, to issue additional equity securities or enter into other financing arrangements for a portion of our future capital ~~needs; there~~needs. There is no guarantee that we will be successful in issuing additional equity securities or entering into other financing arrangements.

35

38

PART I – FINANCIAL INFORMATION

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We have interest rate and foreign exchange rate risk exposure but no long-term fixed rate investments or borrowings. Our primary interest rate risk is due to potential fluctuations of interest rates for short-term investments.

Foreign exchange risk exposure arises because we market and sell our products throughout the world. Revenues in certain foreign countries as well as certain expenses related to those revenues are transacted in currencies other than the U.S. dollar. Our operating results are exposed to changes in exchange rates between the U.S. dollar and the British pound sterling, euro, Mexican peso, Brazilian real, Chinese yuan, Australian dollar, ~~and to a lesser extent, the~~ Thai baht, Japanese yen, South Korean won and to a lesser extent, the Indian rupee, Canadian dollar, Guatemalan quetzal, Argentine peso, Uruguayan peso and Chilean ~~peso; there~~peso. There is also exposure to a change in exchange rate between the British pound sterling and the euro. When the U.S. dollar weakens against foreign currencies, the dollar value of revenues denominated in foreign currencies increases. When the U.S. dollar strengthens, the opposite situation occurs. Additionally, previously invoiced amounts can be positively or negatively affected by changes in exchange rates in the course of collection. We use derivative financial instruments to help manage the economic impact of fluctuations in certain currency exchange rates. These contracts are adjusted to fair value through earnings.

Neogen has assets, liabilities and operations outside of the U.S., located in Scotland, England, Ireland, Italy, Switzerland, Poland, Brazil, Mexico, Guatemala, Argentina, Uruguay, Chile, Colombia, China, Thailand, Japan, Korea, India, Canada and Australia where the functional currency is the British pound sterling, euro, Brazilian real, Mexican peso, Guatemalan quetzal, Argentine peso, Uruguayan peso, Chilean peso, Colombian peso, Chinese yuan, Thai baht, Japanese yen, South Korean won, Indian rupee, Canadian dollar and Australian dollar, respectively. Our investments in foreign subsidiaries are considered long-term. As discussed in ITEM 1A. RISK FACTORS of our Annual Report on Form 10-K for the year ended May 31, 2022, our financial condition and results of operations could be adversely affected by currency fluctuations.

The following table sets forth the potential loss in future earnings or fair values, resulting from hypothetical changes in relevant market rates or prices:

~~Risk Category~~

~~Hypothetical Change~~

~~November 30, 2022~~

~~Impact~~


Risk Category	Hypothetical Change	February 28, 2023		Impact
(dollars in thousands)
Foreign Currency—Revenue	10% Decrease in exchange rates	$	43,334	Earnings
Foreign Currency—Hedges	10% Decrease in exchange rates		1,850	Fair Value
Interest Income	10% Decrease in interest rates		194	Earnings
Interest Expense	10% Increase in interest rates		1,998	Earnings

39

~~(dollars in thousands)~~

~~Foreign Currency—Revenue~~

~~10% Decrease in exchange rates~~

~~$ 46,248~~

~~Earnings~~

~~Foreign Currency—Hedges~~

~~10% Decrease in exchange rates~~

~~15,021~~

~~Fair Value~~

~~Interest Income~~

~~10% Decrease in interest rates~~

~~127~~

~~Earnings~~

~~Interest Expense~~

~~10% Increase in interest rates~~

~~2,068~~

~~Earnings~~

PART I – FINANCIAL INFORMATION

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

An evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of ~~November 30, 2022~~February 28, 2023 was carried out under the supervision and with the participation of the Company’s management, including the President & Chief Executive Officer and ~~the Vice President &~~ Chief Financial Officer (“the Certifying Officers”). Based on the evaluation, the Certifying Officers concluded that the Company’s disclosure controls and procedures are effective.

Changes in Internal Controls over Financial Reporting

No changes in our control over financial reporting were identified as having occurred during the quarter ended ~~November 30, 2022~~February 28, 2023 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

36

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

For a description of our material pending legal proceedings, see Note 12 “Commitments and Contingencies” of the Notes to interim condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, which is incorporated by reference.

Item 1A. Risk Factors

~~Item 1A.~~

~~Risk Factors~~

This Form 10-Q should be read in conjunction with Part I Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended May 31, 2022. There have been no material changes in the risk factors described in our Annual Report on Form 10-K for the year ended May 31, 2022.

Items 2, 3, 4, and 5 are not applicable or removed or reserved and have been omitted.

37

I~~tem~~

40

Item 6. Exhibits

(a) Exhibit Index


~~2.1~~		Agreement and Plan of Merger, dated as of December 13, 2021, by and among 3M Company, Garden SpinCo Corporation, Neogen Corporation and Nova RMT Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Neogen Corporation on December 15, 2021).

~~2.2~~		Separation and Distribution Agreement, dated as of December 13, 2021, by and among 3M Company, Garden SpinCo Corporation and Neogen Corporation (incorporated by reference to Exhibit 2.2 to the Current Report on Form 8-K filed by Neogen Corporation on December 15, 2021).

~~2.3~~		Amendment No. 1 to the Separation and Distribution Agreement, dated as of August 31, 2022, by and among 3M Company, Garden SpinCo Corporation and Neogen Corporation (incorporated by reference to Exhibit 2.2 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

~~2.4~~		Asset Purchase Agreement, dated as of December 13, 2021, by and between 3M Company and Neogen Corporation (incorporated by reference to Exhibit 2.3 to the Current Report on Form 8-K filed by Neogen Corporation on December 15, 2021).

~~3.1~~		~~Certificate of Amendment to Articles of Incorporation filed on October 11, 2010 (incorporated by reference to Exhibit 3.2 filed with the Registrant’s Annual Report on Form~~ ~~10-K~~ ~~filed on July 30, 2020).~~

~~3.2~~		~~Restated Articles of Incorporation, as amended on November 23, 2011 (incorporated by reference to Exhibit 3.1 filed with the Registrant’s Quarterly Report on Form~~ ~~10-Q~~ ~~filed December 30, 2011).~~

~~3.3~~		~~Certificate of Amendment to Articles of Incorporation filed on November 20, 2018 (incorporated by reference to Exhibit 3 filed with the Registrant’s Quarterly Report on Form~~ ~~10-Q~~ ~~filed December 28, 2018).~~

~~3.4~~		~~Certificate of Amendment to Articles of Incorporation of Neogen Corporation filed on March 14, 2022 (incorporated by reference to Exhibit 3.1 to the Current Report on Form~~ ~~8-K~~ ~~filed by Neogen Corporation on March 17, 2022).~~

~~3.5~~		~~Certificate of Amendment to Articles of Incorporation of Neogen Corporation filed on September 1, 2022 (incorporated by reference to Exhibit 3.1 to the Current Report on Form~~ ~~8-K~~ ~~filed by Neogen Corporation on September 1, 2022).~~

~~3.6~~		~~By-Laws,~~ ~~as amended (incorporated by reference to Exhibit 3.2 to the Registrant’s Quarterly Report on Form~~ ~~10-Q~~ ~~filed April 14, 2000).~~

~~3.7~~		~~Amendment to the~~ ~~By-Laws,~~ ~~as amended (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form~~ ~~8-K~~ ~~filed by Neogen Corporation on September 1, 2022).~~

~~4.1~~		Senior Notes Indenture for 8.625% Senior Notes due 2030, dated as of July 20, 2022, among Garden SpinCo Corporation, as issuer, the guarantors party thereto from time to time, and U.S. Bank Trust Company, National Association, as trustee (incorporated by reference to Exhibit 10.10 to Neogen’s Registration Statement on Form S-4 (Registration No. 333-263667), filed with the SEC on July 27, 2022).

~~4.2~~		Supplemental Indenture, dated as of September 1, 2022, among Neogen Food Safety Corporation (f/k/a Garden SpinCo Corporation), as issuer, U.S. Bank Trust Company, National Association, as trustee, Neogen Corporation and certain of its subsidiaries (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

~~10.1~~		Tax Matters Agreement, dated as of September 1, 2022, by and among 3M Company, Garden SpinCo Corporation and Neogen Corporation (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

~~10.2~~		Intellectual Property Cross-License Agreement, dated as of September 1, 2022, by and between 3M Company and Garden SpinCo Corporation (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

~~10.3~~		Trademark Transitional License Agreement, dated as of September 1, 2022, by and among 3M Company, 3M Innovative Properties Company, Neogen Corporation and Garden SpinCo Corporation (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

~~10.4~~		Transition Services Agreement, dated as of September 1, 2022, by and among 3M Company, Garden SpinCo Corporation and Neogen Corporation (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

~~10.5~~		Transition Distribution Services Agreement, dated as of September 1, 2022, by and among 3M Company, Garden SpinCo Corporation and Neogen Corporation (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

~~10.6~~		Transition Contract Manufacturing Agreement, dated as of September 1, 2022, by and among 3M Company, Garden SpinCo Corporation and Neogen Corporation (incorporated by reference to Exhibit 10.6 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

~~10.7~~		Clean-Trace(TM) Distribution Agreement, dated as of September 1, 2022, by and between 3M Company and Garden SpinCo Corporation (incorporated by reference to Exhibit 10.7 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).
31.1
~~10.8~~		Real Estate License Agreement, dated as of September 1, 2022, by and among certain subsidiaries of Neogen Corporation, 3M Company and certain of its subsidiaries (incorporated by reference to Exhibit 10.8 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

~~10.9~~		Credit Agreement, dated as of June 30, 2022, among Garden SpinCo Corporation, as borrower, the lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as administrative agent, and joined thereto as of September 1, 2022 by Neogen Corporation, as a borrower (incorporated by reference to Exhibit 10.9 to Neogen’s Registration Statement on Form ~~S-4~~ ~~(Registration~~ ~~No. 333-263667),~~ ~~filed with the SEC on July 27, 2022).~~

~~31.1~~		Certification of Principal Executive Officer

31.2		Certification of Principal Financial Officer

32		Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

38

41

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

NEOGEN CORPORATION

(Registrant)

Dated: ~~January 9,~~April 4, 2023

/s/ John E. Adent

John E. Adent

President & Chief Executive Officer

(Principal Executive Officer)

Dated: ~~January 9,~~April 4, 2023

/s/ ~~Steven J. Quinlan~~David H. Naemura

~~Steven J. Quinlan~~

David H. Naemura

~~Vice President &~~

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

42

39


	November 30, 2022			May 31, 2022
Assets
Current Assets
Cash and cash equivalents	$	100,000		$	44,473
Marketable securities		176,338			336,578
Accounts receivable, net of allowance of $1,950 and $1,650		142,711			99,674
Inventories		136,069			122,313
Prepaid expenses and other current assets		88,215			23,760

Total Current Assets		643,333			626,798
Net Property and Equipment		148,170			110,584
Other Assets
Right of use assets		3,707			3,184
Goodwill		2,122,397			142,704
Other non-amortizable intangible assets		15,216			15,397
Amortizable intangible and other assets, net of accumulated amortization of $78,046 and $55,416		1,626,514			92,106
Other non-current assets		3,905			2,156

Total Assets	$	4,563,242		$	992,929

Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable	$	79,251		$	34,614
Accrued compensation		15,014			11,123
Income tax payable		9,049			2,126
Accrued interest		13,974			—
Deferred revenue		5,083			5,460
Other accruals		30,187			24,521

Total Current Liabilities		152,558			77,844
Deferred Income Tax Liability		364,252			17,011
Non-current debt		923,962			—
Other non-current liabilities		16,207			10,700

Total Liabilities		1,456,979			105,555
Commitments and Contingencies (note 12)
Equity
Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding		—			—
Common stock, $0.16 par value, 315,000,000 shares authorized, 216,154,283 and 107,801,094 shares issued and outstanding at November 30, 2022 and May 31, 2022, respectively		34,584			17,248
Additional paid-in capital		2,560,898			309,984
Accumulated other comprehensive loss		(40,498	)		(27,769	)
Retained earnings		551,279			587,911

Total Stockholders’ Equity		3,106,263			887,374

Total Liabilities and Stockholders’ Equity	$	4,563,242		$	992,929


(in thousands)	November 30, 2022		May 31, 2022
Raw materials	$	68,884	$	58,667
Work-in-process		6,013		6,388
Finished and purchased goods		61,172		57,258

	$	136,069	$	122,313


	Three Months ended November 30,				Six Months ended November 30,
(in thousands)	2022		2021		2022		2021
Food Safety
Natural Toxins, Allergens & Drug Residues	$	22,251	$	21,028	$	42,038	$	41,432
Bacterial & General Sanitation		41,121		12,252		51,849		23,421
Culture Media & Other		82,084		19,935		101,338		37,981
Rodent Control, Insect Control & Disinfectants		10,377		8,232		19,952		15,882
Genomics Services		5,510		5,685		10,809		11,138

		161,343		67,132		225,986		129,854
Animal Safety
Life Sciences		1,427		1,309		3,016		2,672
Veterinary Instruments & Disposables		16,433		15,572		31,106		30,909
Animal Care & Other		10,569		10,849		21,095		20,068
Rodent Control, Insect Control & Disinfectants		20,665		18,269		42,879		40,418
Genomics Services		19,596		17,386		38,300		34,901

		68,690		63,385		136,396		128,968

Total Revenues	$	230,033	$	130,517	$	362,382	$	258,822


(in thousands)	Food Safety		Animal Safety		Corporate and Eliminations (1)			Total
As of and for the three months ended November 30, 2022
Product revenues to external customers	$	154,223	$	49,094	$	—		$	203,317
Service revenues to external customers		7,120		19,596		—			26,716

Total revenues to external customers	$	161,343	$	68,690	$	—		$	230,033

Operating income (loss)	$	21,446	$	12,806	$	(41,908	)	$	(7,656	)
Total assets	$	3,955,488	$	329,177	$	278,577		$	4,563,242

As of and for the three months ended November 30, 2021
Product revenues to external customers	$	60,112	$	45,999	$	—		$	106,111
Service revenues to external customers		7,020		17,386		—			24,406

Total revenues to external customers	$	67,132	$	63,385	$	—		$	130,517

Operating income (loss)	$	10,894	$	12,701	$	(11,126	)	$	12,469
Total assets	$	298,437	$	278,994	$	390,503		$	967,934


(options in thousands)	Shares			Weighted- Average Exercise Price
Options outstanding June 1, 2022		3,244		$	32.13
Granted		1,687			14.63
Exercised		(4	)		10.75
Forfeited/Expired		(592	)		29.75

Options outstanding November 30, 2022		4,335		$	25.66


	FY 2023			FY 2022
Risk-free interest rate		3.3	%		0.4	%
Expected dividend yield		0.0	%		0.0	%
Expected stock price volatility		34.0	%		32.8	%
Expected option life		4.61 years			3.12 years


(RSUs in thousands)	Shares			Weighted- Average Fair Value
RSUs outstanding June 1, 2022		257		$	36.14
Granted		584			13.72
Released		(47	)		37.62
Forfeited/Cancelled		(5	)		37.63

RSUs outstanding November 30, 2022		789		$	19.46


(in thousands)	As of November 30, 2022			As of May 31, 2022
Term Loan	$	590,000		$	—
Senior Notes		350,000			—

Total long-term debt	$	940,000		$	—
Less: Unamortized debt issuance costs		(16,038	)		—

Total non-current debt, net	$	923,962		$	—